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ABSTRACT 
In recent years, the transplant community has explored and adopted tools for 
quantifying clinical insight into illness severity and frailty. This dissertation work 
explores the interplay between objective and subjective assessments of physical health 
status and the implications for liver transplant candidate and recipient outcomes. The first 
aim characterizes national epidemiologic trends and the impact of Centers for Medicare 
and Medicaid quality improvement policies on likelihood of waitlist removal based on 
the patient being too frail to benefit from liver transplant (“too sick to transplant”). This 
aim includes more than a decade (2002–2012) of comprehensive national transplant 
waitlist data (Scientific Registry of Transplant Recipients (SRTR)). The second aim will 
assess and define objective parameters of liver transplant patient frailty by measuring 
decline in lean core muscle mass (“sarcopenia”) using abdominal CT scans collected 
retrospectively at a single U.S. transplant center between 2006 and 2015. The relationship 
between these objective sarcopenia measures and subjective functional status assessed 
using the Karnofsky Functional Performance (KPS) scale are described and quantified. 
The third aim quantifies the extent to which poor functional status (KPS) pre-transplant is 
associated with worse post-transplant survival and includes national data on liver 
transplantations conducted between 2005 and 2014 (SRTR). The results of this 
dissertation will help providers in the assessment of frailty and subsequent risk of adverse 
outcomes and has implications for strategic clinical management in anticipation of 
surgery. This research will also to serve to inform national policy on the design of 
transplant center performance measures. 
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CHAPTER I 
INTRODUCTION 
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Liver Disease and Transplantation 
Liver disease is the 4th leading cause of death among Americans aged 45–54 years 
old and the 12th leading cause of death overall (2–4). The mortality rate among patients 
with advanced liver disease is approximately 26% per 2-year interval (3). Liver disease 
results in over 1.2 million hospitalizations per year (5), with direct and indirect costs 
estimated at upwards of $13.1 billion annually (6,7). In 2012, over 3 million U.S. adults 
were estimated to be affected with liver disease, and the incidence has been on the rise 
(8). While there are more than 100 types of liver disease, over half of all cases are due to 
viral hepatitis, predominantly hepatitis C, followed by alcohol and non-alcoholic 
steatohepatitis, a component of metabolic syndrome (3).  
The liver is the largest organ in the human body and serves over 2000 metabolic 
functions, including regulation of metabolism and nutrients, detoxification, and synthesis 
of bile and proteins such as albumin and coagulation factors. In order to serve these 
functions, virtually all venous drainage from the stomach, intestines, pancreas, and spleen 
pass through the liver. Thus, chronic liver damage can lead to consequences for many of 
these and other organ systems as well. Clinical manifestations of liver disease are 
heterogeneous, systemic, and often unpredictable. Largely attributable to the diversity 
and complexity of liver disease, transplant is the mainstay of treatment for end-stage liver 
disease; there is no equivalent to hemodialysis as for end-stage kidney disease (9). 
The field of liver transplantation faces dramatic and worsening shortages in organ 
availability. Although 5,921 adult liver transplants were performed in the U.S. in 2013, 
15,027 candidates remained on the waiting list on December 31 of that year (10). In 
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2002, in response to increasing shortages and waitlist mortality, the liver allocation 
system was reorganized to prioritize patients according to urgency. The conceptual 
definition of “urgency” was operationalized as calculated risk of 3-month mortality 
according to the Model for End-Stage Liver Disease (MELD) score, which is based on 3 
objective laboratory parameters. However, MELD was originally designed for a different 
purpose - to predict the risk of procedure-related mortality for placement of Transjugular 
Intrahepatic Portosystemic Shunt - and the new system has required multiple adaptations 
to correct for subpopulations for which MELD score underestimates mortality (11–14). In 
the context of a disease with such a broad range of causes and manifestations, accurately 
defining “urgency” using only 3 objective parameters, and at only one time point, comes 
with inherent challenges (15). The current allocation system has continuously evolved 
and will likely continue to mature with each subsequent modification for many years to 
come (16–29). 
It has been shown that MELD score underestimates the risk of both waitlist and 
post-transplant mortality among patients who are frail (25,30,31). It is hypothesized that 
progressive malnutrition, muscle wasting (“sarcopenia”), and subsequent functional 
decline, all hallmark sequelae of liver disease, result in a frailty phenotype wherein 
patients are more vulnerable to stressors such as surgery and infection due to limited 
physiologic reserve (Figure 1.1) (30,32–39).  
In recent years, the transplant community has explored and adopted tools for 
better quantifying clinical insight into illness severity and frailty. Recent research has 
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shown that clinician assessment of illness severity (commonly referred to as the “eye-ball 
test”) is predictive of waitlist mortality independent of MELD score (31).  
Research on quantifying risk of post-transplant mortality, for which there is no 
equivalent to MELD score for pre-transplant mortality in terms of both predictive ability 
and generalizability, is very active and much needed in the field today. Several 
components of frailty syndrome, including sarcopenia as well as functional status, have 
been associated with poor morbidity and mortality outcomes after many different types of 
surgeries, including after liver transplantation (34,35,38,40–67).  
Muscle wasting is one of many pathognomonic consequences of end-stage liver 
disease. Sarcopenia describes a combination of decrease in muscle mass and quality due 
to decrease in muscle fiber number and size, strength, and subsequently, functional 
performance (68–71). It is a key component of frailty syndrome (Figure 1.1) and may be 
key to quantifying and understanding frailty syndrome in a liver transplant population. 
One biologic mechanism that has been proposed to explain the discrepancy between 
MELD-based mortality estimates and actual risk among frail patients for whom MELD 
score underestimated mortality risk, is that creatinine concentration, the primary driver of 
MELD score, is proportional to muscle mass, and with muscle wasting being a major 
component of both frailty and liver disease, MELD may be disproportionate to extent of 
liver disease in these patients (Figure 1.2).  
Clinical manifestations of frailty and impaired functional status in liver 
transplantation may not be as directly related to each other in liver transplant patients as 
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is illustrated in the context of a geriatric population in Figure 1.1; there may be many 
additional consequences of end-stage liver disease that may result in disability and not 
previously illustrated in other populations, and this tool must still be refined for this 
population.  
 
Translation of “Frailty Syndrome” for an End-Stage Liver Disease Population  
The concept of “frailty syndrome” originated from a geriatric framework. 
Diagnostic criteria and definitions of “frailty” are heterogeneous across geriatric, 
nutritional sciences, nursing/rehabilitation, and surgical bodies of literature 
(32,34,40,41,43–50,54,56,59,61,65,68–136). It describes a dynamic and potentially 
modifiable phenomenon of decreasing strength, function, and overall health status as a 
result of advanced age, chronic malnutrition, comorbidities and other systemic 
dysfunctions (Figure 1.1) (85,86,104,108,136).  
Although many of the definitions and objective measures of frailty that were 
developed in non-transplant populations have been widely validated (125), there are 
important differences in these populations that limit their direct translation. For example, 
whereas age was originally conceptualized as the primary driver of frailty among 
geriatric populations, and cachexia, an irreversible progressive inflammation-based is the 
driver of frailty in oncology populations, it is actually “secondary sarcopenia,” due to 
chronic disease and malnutrition (79), that drives frailty in end-stage liver disease. 
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Disease courses and prognoses in these populations also differ dramatically. In the 
original populations where frailty is described, frailty is conceptualized as progressive 
and mostly irreversible. This is in contrast to a liver disease population, which may have 
some, or potentially all, of these processes reversed after replacing the non-functioning 
organ with a new, non-diseased organ. 
Recommendations regarding frailty cut-points or thresholds, as well as treatment 
strategies and implications for prognoses, are dependent on the relative potential benefit 
of a particular treatment such as surgery compared to the risk of undergoing the surgery 
(also referred to as “futility” of transplant). Interventions that may slow frailty and 
sarcopenia progression, such as nutritional supplementation and strength/resistance 
muscle training have been hypothesized across many populations (54–57,60–62,137–
139). However, as the underlying etiologies are hypothesized to differ greatly, 
interventions may also need to target different deficits or approach the deficits 
differently. 
 
This dissertation addresses an important gap in the literature by working toward 
an updated framework and approach to measuring and defining “frailty syndrome” that is 
specific to a liver transplant population. 
 
Specific Aims 
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This dissertation examines the interplay between frailty, functional status, 
transplant outcomes. The first aim characterizes national epidemiologic trends in 
incidence of waitlist removal on account of the patient being too frail to benefit from 
transplant (“too sick to transplant”), using more than a decade of national data (Scientific 
Registry of Transplant Recipients (SRTR)) from 2002 to 2012. The second aim explores 
objective parameters of liver transplant patient frailty by measuring decline in lean core 
muscle mass (“sarcopenia”) using abdominal CT scans collected retrospectively at a 
single U.S. transplant center between 2006 and 2015 (42,43,47). The relationship 
between these objective sarcopenia measures and subjective functional status, assessed 
by transplant providers using the Karnofsky Functional Performance scale (Table 1.1), is 
then described and quantified. The third and final aim seeks to quantify the extent to 
which poor pre-transplant functional status (KPS) is associated with worse post-liver 
transplant outcomes using national data from 2005 to 2014 (SRTR).  
The specific aims of this dissertation were as follows. 
 
Aim 1. To evaluate the impact of transplant policy on incidence of candidate delisting 
due to “too sick to transplant.” 
Hypothesis 1.1: Incidence has been increasing since implementation of CMS 
Conditions of Participation (2007).  
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Aim 2. To describe the relationship between objective (sarcopenia) and subjective 
(functional status, KPS) measures of pre-transplant frailty among liver transplant 
recipients using single center data. 
Hypothesis 2.1: Sample distribution of muscle mass and sarcopenia would vary 
by gender, time on the waiting list, MELD, and medical condition. 
Hypothesis 2.2: Poorer functional status at transplant will be correlated with 
greater extent of sarcopenia. 
 
Aim 3. To quantify the extent to which patients that are of poor functional status pre-
transplant are at increased risk of 1-year post-transplant mortality and graft failure. 
Hypothesis 3.1: Both Low and Moderate functional status would be associated 
with worse survival 1 year after liver transplantation. 
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Table 1.1: Karnofsky Performance Status scale and variable handling 
KARNOFSKY PERFORMANCE STATUS SCALE 
Condition* % Rating Criteria 
   A  
(“None/Normal”) 
 
Able to carry on normal 
activity and to work; no special 
care needed. 
100 Normal, no complaints; no evidence of disease. 
90 Able to carry on normal activity; minor signs 
or symptoms of disease. 
80 Normal activity with effort; some signs or 
symptoms of disease.  
   B  
(“Moderate”) 
 
Unable to work; able to live at 
home and care for most 
personal needs; varying amount 
of assistance needed. 
70 Cares for self; unable to carry on normal 
activity or to do active work. 
60 Requires occasional assistance, but is able to 
care for most of his personal needs. 
50 Requires considerable assistance and frequent 
medical care.  
   C 
(“Severe”) 
 
Unable to care for self; 
requires equivalent of 
institutional or hospital care; 
disease may be progressing 
rapidly. 
40 Disabled; requires special care and assistance. 
30 Severely disabled; hospital admission is 
indicated although death not imminent. 
20 Very sick; hospital admission necessary; active 
supportive treatment necessary. 
10 Moribund; fatal processes progressing rapidly. 
0 Dead 
*Author-assigned variable labels in parentheses 
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Figure 1.1: Cycle of frailty hypothesized as consistent with demonstrated pairwise 
associations and clinical signs and symptoms of frailty (Fried et al 2001). 
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Figure 1.2: Conceptual model of the relationship between frailty, Model for End-Stage 
Liver Disease (MELD) and adverse outcomes as pertaining to liver transplantation (Lai et 
al 2014).  
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CHAPTER II 
DECADE-LONG TRENDS IN LIVER TRANSPLANT WAITLIST REMOVAL 
DUE TO ILLNESS SEVERITY: THE IMPACT OF CENTERS FOR MEDICARE 
AND MEDICAID POLICY 
13 
 
ABSTRACT 
Background: The central tenant of liver transplant allocation is to prioritize the sickest 
first. However, a 2007 Centers for Medicare and Medicaid (CMS) regulatory policy, 
"Conditions of Participation (COP)," which mandates publically reported transplant 
center performance assessment and outcomes-based auditing, critically altered waitlist 
management and clinical decision-making. We examine the extent to which COP 
implementation is associated with increased removal of the "sickest" patients from the 
liver transplant waitlist. 
Study Design: This study included 90,765 adult (≥ 18 years old) deceased donor liver 
transplant candidates listed at 102 transplant centers from April 2002 to December 2012 
(Scientific Registry of Transplant Recipients). We quantified the effect of COP 
implementation on trends in waitlist removal due to "illness severity," and one-year post-
transplant mortality using interrupted time series segmented Poisson regression analysis. 
Results: We observed increasing trends in delisting due to "illness severity" in the setting 
of comparable demographic and clinical characteristics. Delisting abruptly increased by 
16% at the time of COP implementation, and the likelihood of being delisted continued to 
increase by 3% per quarter thereafter, without attenuation (p < 0.001). Results remained 
consistent after stratifying on key variables (MELD, age). COP did not significantly 
affect 1-year post-transplant mortality (p = 0.38).  
Conclusions: Although the CMS Conditions of Participation policy (2007) was a quality 
initiative designed to improve patient outcomes, in reality, it failed to show beneficial 
14 
 
effects in the liver transplant population. Patients who could potentially benefit from 
transplant are increasingly being denied this life-saving procedure while transplant 
mortality rates remain unaffected. Policy makers and clinicians should strive to balance 
candidate and recipient needs from a population-benefit perspective when designing 
performance metrics and during clinical decision-making for patients on the waitlist. 
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INTRODUCTION 
The current Model for End-Stage for Liver Disease (MELD)-based liver 
allocation system was introduced in 2002 in response to rising waitlist mortality in the 
setting of increasingly limited resources (organs) relative to rising demand. MELD is 
based on the fundamental principle that scarce resources should be allocated to those 
most in need (“sickest first”). Though waitlist mortality has stabilized since the 
introduction of the MELD system, removal of patients “too sick to transplant” has been 
on the rise (53,63,140–145). This clinical decision invariably results in patient death 
without a transplant; an estimated 80% will die within 2 weeks of waitlist removal (145). 
The MELD score, calculated using 3 laboratory values (creatinine, international 
normalized ratio, bilirubin), is used to rank candidates within transplant centers’ waiting 
lists. It allows the local or regional organ bank to easily and objectively sort potential 
recipients of a new organ offer. However, the composition of waiting lists and decisions 
on whether to accept or reject an organ once offered are made at the level of the 
transplant center. These decisions take into account not only the risk status of the patient 
and organ, but are also affected by institution-level financial pressures and potential 
regulatory consequences of high-risk transplantation (146–148).  
In 2007, the Centers for Medicaid and Medicare Services (CMS) implemented the 
policy, Conditions of Participation (COP) (149,150). This regulatory policy uses 
Scientific Registry of Transplant Recipient (SRTR)-generated transplant program-
specific performance reports to audit and publically report “underperforming” transplant 
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centers. This puts centers at risk for losing contracts with CMS and exclusion from 
private insurance “Centers of Excellence” networks, among other consequences 
(151,152). However, the policy only evaluates post-transplant survival. Without the 
consideration of waitlist outcomes, COP has led to unintended consequences for patients. 
Centers that have been flagged as “underperforming” have been shown to exhibit risk 
aversion with respect to candidate and donor selection (146,147,151,153–161), decreased 
waitlist and transplant volume (157,162), and prolonged waiting times (163,164). These 
changes ultimately result in reduced access to essential resources for patients, changing 
definitions of transplant “futility” toward conservatism, and conflict with the central tenet 
of modern transplant allocation: to prioritize the sickest patients first. 
The purpose of this study was to evaluate whether known effects of COP flagging 
at the transplant center level translate to meaningful changes in waitlist dynamics at the 
national level. Specifically, we use more than a decade of comprehensive national data to 
describe and quantify the extent to which trends in candidate waitlist removal for being 
“too sick to transplant” were altered in the short- and long-term after the introduction of 
the COP policy. Further, we will examine whether COP implementation resulted in worse 
overall (waitlist and post-transplant) population survival. 
 
METHODS 
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Study Population 
This study used data from the Scientific Registry of Transplant Recipients 
(SRTR). The SRTR data system includes data on all donor, wait-listed candidates, and 
transplant recipients in the U.S., submitted by the members of the Organ Procurement 
and Transplantation Network (OPTN). The Health Resources and Services 
Administration, U.S. Department of Health and Human Services provides oversight to the 
activities of the OPTN and SRTR contractors. 
This quasi-experimental (retrospective) study includes adults (≥ 18 years old) on 
U.S. deceased donor liver transplant waitlists for first liver transplant between April 1, 
2002 and December 31, 2012, inclusive (Figure 1). Patients listed with hepatocellular 
carcinoma were excluded because, for this indication, waitlist removal due to condition 
deterioration is primarily based on objective measures of tumor progression (Milan 
criteria) and these patients are removed by mandate rather than clinical judgment. 
Furthermore, allocation policies have changed multiple times over the course of the study 
period for these patients (165,166).  
Subjects listed at transplant centers with very small or fluctuating waitlist 
volumes, as defined in earlier literature (167), where each quarter that a candidate was on 
the waiting list was counted as a unique observation, were excluded (Figure 1). For 
patients listed at multiple centers, one record was chosen at random using a computer-
generated randomization schema. 
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Comparison Groups 
The key intervention of interest was implementation of Centers for Medicare and 
Medicaid (CMS) “Conditions of Participation (COP)” on June 28, 2007 (153). Our 
intervention group consisted of observations occurring after COP implementation (July 1, 
2007–December 31, 2012). Pre-intervention observations (April 1, 2002–June 30, 2007) 
were categorized as the referent group (168).  
 
Study Outcomes 
The primary outcome of interest was the proportion of candidates removed from 
the waiting list due to “illness severity” per thousand candidates on the waitlist at any 
time during the respective quarter. Transplant centers are required to report reason for 
waitlist removal (including reasons such as transplant or death); we used the codes “13: 
Candidate Condition Deteriorated, Too Sick for Transplant,” and “5: Medically 
Unsuitable” to define removal due to “illness severity.” Because “Medically Unsuitable” 
represented < 0.2% of events in our population, we use the terms “illness severity” and 
“too sick” interchangeably to refer to the primary outcome. 
The secondary outcome of interest was 1-year post-liver transplant mortality, 
defined as the proportion of patients transplanted per quarter that did not survive to 
postoperative day 365 (Social Security Death Master File, Organ Procurement and 
Transplant Network). 
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Potential confounders were selected through review of the published literature and 
a priori clinical knowledge (63,141,169). Patient characteristics known at the time of 
waitlist registration that, 1) are potential risk factors for waitlist removal due to illness 
severity, and 2) may have different prevalence estimates pre- versus post-COP 
implementation, were considered potential confounders. All MELD scores reported 
represent laboratory-calculated MELD scores. 
 
Statistical Analysis 
We explored key study variables both graphically (time series plots) and using 
contingency table analyses to compare changes in patient characteristics pre- and post- 
COP policy implementation. We then used interrupted time series analysis to explore 
trends in candidate delisting and 1-year post-transplant mortality. Quantitative evaluation 
of immediate and long-term policy impacts was conducted using segmented Poisson 
regression adjusted for pre-intervention trends, which serve as a historical control 
(referent group) against which the post-intervention trends are compared (168,170). 
Models were fit using Newey-West standard errors to account for potential correlation in 
the outcomes at adjacent time points (171). To evaluate potential time-varying 
confounding, the primary model was stratified on each variable observed to have 
meaningfully different prevalence estimates pre-post COP (Table 1). 
To facilitate comparison of waitlist removal model results to transplant survival 
model results, we restricted the modeling period to April 1, 2003–December 31, 2011 
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only. This start date was selected based on observed instability in waitlist trends during 
the first year after MELD implementation (n = 6,953 waitlist candidates and n = 3,546 
transplants excluded, Figures 2 and 3). This end date was selected in order to allow for 
complete ascertainment of 1-year post-transplant survival (n = 7,079 candidates and n = 
3,555 transplants excluded). The final regression models included 76,733 candidates 
(44,085 pre-COP, 45,892 post-COP) and 34,603 transplants (17,630 pre-COP, 16,973 
post-COP), respectively. 
After confirming comparability (e.g. age, sex, race, transplant center) among 
delisted patients with versus without death data available (144), we qualitatively 
compared 1-year survival after waitlist removal to 1-year survival after transplant to 
explore whether there was a net change in outcomes at the population-level, pre-post 
COP. 
Results are reported as population-level incidence rate ratios (95% confidence 
intervals (CI); p-value ≤ 0.05 was considered statistically significant). All analyses were 
conducted using Stata version 13 (StataCorp LP, College Station, TX). This study was 
deemed exempt by the University of Massachusetts Medical School Institutional Review 
Board. 
 
RESULTS 
The final study sample included 90,765 liver transplant candidates on waitlists at 
102 unique transplant centers between 2002 and 2012. The mean waitlist volume by 
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center ranged from 1 to 742 candidates per quarter. The median age of candidates at 
listing was 53 years, 38.3% were women, and 14.2% were Hispanic/Latino and 8.3% 
African American. The median MELD score at listing was 15. The median time on the 
waitlist was 6.6 months, and the median time to transplant was 2.5 months.  
Table 1 describes the waitlist population pre-post Conditions of Participation 
(COP) implementation using information known at the time of waitlist registration. 
Although all pre-post comparisons were statistically significant due to the large sample 
size, baseline characteristics were relatively similar pre-post COP. The greatest changes 
in patients’ characteristics over time were observed as proportion of patients aged 55 
years and older (10.2% absolute increase) and MELD score of less than 15 at listing 
(7.6% decrease). 
Table 2 compares the characteristics of waitlist candidates removed due to illness 
severity and characteristics of transplant recipients, pre-post COP. Of the 90,765 
candidates on the liver transplant waitlist between 2002 and 2012, 7.3% were removed 
due to illness severity (“too sick,” n = 6,972; “medically unsuitable,” n = 12).  
Almost twice as many patients were removed after COP implementation (n = 
4,340) than before (n = 2,311). By the end of 2012, incidence increased from 8.6 in the 
quarter immediately following COP implementation (2007, Quarter 3) to 19.7 at the end 
of 2012. The ratio of patients delisted-to-transplanted increased from 1 delisting for every 
9 transplants to 1 delisting per every 5 transplants, on average. 
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Compared to before COP implementation, patients who were delisted post-COP 
were older (the proportion of patients 55 years or older increased by an absolute 12.4%) 
and more often without private insurance (4.6% absolute increase, compared with 2.5% 
increase among transplanted patients) (Table 2). End-MELD scores of ≥ 35 represented a 
greater proportion of delisted patients pre-post COP (6.6% increase) while MELD < 15 
decreased by 5.8% (absolute changes). The proportion of delisted patients who 
underwent dialysis in the week prior to transplant versus waitlist delisting increased by 
5.8% pre-post versus 9.3%, respectively. 
Figure 2 is a time-series plot of the incidence of delisting due to illness severity 
over time. We observed increasing trends in the incidence of candidate delisting due to 
illness severity throughout the study period. While there was a baseline trend of 
increasing incidence, a marked change can be observed at time of COP implementation. 
In the first quarter immediately after COP went into effect, the number of patients 
delisted (per 1,000 candidates) abruptly increased by 16% (p < 0.001) (Table 3). The 
incidence rate continued to increase at a rate of 3% (p < 0.001) per quarter thereafter, 
with no sign of attenuation. 
Upon stratification of delisting trends by key sociodemographic and illness 
factors, COP was observed to have a greater impact for patients with higher MELD 
scores at delisting (Figure 3B) and older patients (Figure 3D), despite modest, secular 
increases in the variable means over the study period (Figures A and C, respectively). 
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Estimates for each stratified model remained consistent (< 10% change) with whole-
population delisting trends described in Table 3. 
Figure 4 is a time-series plot of the incidence of transplants resulting in recipient 
death within 1 year of transplant. The implementation of COP did not have a statistically 
significant impact on the trends (p = 0.38) or level (p = 0.62) of post-transplant mortality 
rates (Table 3).  
 
Death after “too sick” waitlist removal versus after transplant, pre-post COP 
Eighty-nine percent of transplant candidates removed due to illness severity died 
within 1 year (87.2% pre-COP, 90.0% post-COP), and 52% died within 1 week (missing 
n = 735). Based on these estimates (calculated 1-year mortality among patients not 
missing death data), approximately 1,423 additional candidates died within one-year 
post-waitlist removal after COP implementation than before. In contrast, 87.5% of 
transplant recipients survived to 1-year post-transplant (86.6% pre-COP, 88.5% post-
COP); there were 396 fewer 1-year post-transplant deaths after COP implementation than 
before (Table 3). The result is a net increase of 1,027 one-year deaths (1,423 - 396) post-
COP implementation. 
 
DISCUSSION 
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The COP policy adopted by CMS in 2007 has had a significant nation-wide 
impact on the likelihood that an adult liver transplant candidate will be removed from the 
waiting list due to “illness severity.” The impact was evident immediately after 
implementation, when the national incidence of delisting “too sick” patients increased 
abruptly. The likelihood of candidate delisting continued to increase over the subsequent 
5-year post-COP observation period and failed to show signs of attenuation. COP did not 
significantly impact 1-year post-transplant survival. 
Our findings are supported by earlier literature that has shown the direct effects of 
CMS oversight at the transplant center level. Centers audited for low or near-low 
performance have been shown to reactively accept fewer high-risk candidates for 
transplantation, and reduce procedure and waitlist volumes overall (146,147,151,153–
162). Our findings provide potential answers to questions raised as to whether changes 
that occur after auditing at individual centers (e.g. volume) are adequately compensated 
for by other centers in the region (167). In contrast, we show continuously increasing 
national rates of candidate delisting after COP. One explanation may be that altered risk 
tolerance persists over time, resulting in national incidence rates that accumulate over 
time as additional centers are flagged in subsequent evaluation waves. Another 
explanation may be that definitions of “too sick to transplant,” or, transplant futility, are 
shifting nation-wide, and protocols or risk tolerance are generally changing regardless of 
audit history. 
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This study reveals limited improvement in liver transplant survival despite 
increased rates of waitlist removal among patients considered too high risk (“too sick”) 
for transplant. The lack of significant improvement in post-transplant survival may be 
explained by the inherent complexity of post-liver transplant outcome prediction given 
the multitude of patient, donor, center, and surgical factors that contribute to transplant 
outcomes. Though waitlist mortality can be relatively accurately predicted using the 
MELD score, the added complexity when considering donor and surgical factors, in 
addition to patient factors, has stunted the development of accurate post-transplant 
mortality prediction for many years (20,100,172–181). The current SRTR-generated 
Program Specific Reports, which are used by CMS for assessment of center performance, 
rely on imperfect approaches for determining “expected survival,” against which 
transplant centers’ outcomes are compared, as well as imperfect risk-adjustment of 
center-specific outcomes (151,158,161,182–184). The models suffer from inadequate 
adjustment and the methodology is continuously under study (185) and changing (151). 
Thus, the disconnect between increased delisting of the sickest patients and no change in 
post-transplant outcomes may be partially attributable to heterogeneity in definitions of 
“high risk” in the absence of reliable objective criteria. 
 
Implications of Results 
The central tenant of liver transplant allocation is to prioritize the sickest first. In 
1999, Institute of Medicine recommendations to temper aggressive urgency-based 
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allocation through the “avoidance of futile transplants or wastage of organs” were 
incorporated into the “Final Rule” (186). Today, external regulatory pressure from CMS 
has overpowered the primarily urgency-based allocation system; increasing numbers of 
potentially viable transplant candidates are being turned away since the implementation 
of COP policy. 
Merion and Schaubel propose “population benefit” models that balance urgency 
(pre-transplant mortality) and utility (post-transplant mortality) to prioritize relative 
transplant benefit that maximizes net population life-years (21,169,176,187). Our results 
illustrate that the current system is increasingly moving away from a net benefit approach 
in favor of maximizing transplant outcomes only. For example, although higher MELD 
scores are associated with greater transplant benefit, patients in higher MELD categories 
were being delisted at increasingly higher rates after COP policy went into effect (169). 
As delisting due to illness severity invariably results in death without transplant, COP 
resulted not only in a shift of mortality burden from post-transplant to the waiting list but 
an overall net loss in benefit. 
In an effort to rebalance the scale, the Organ Procurement and Transplant 
Network recently (2014) proposed a new performance assessment tool specifically for 
waitlist outcomes, the “Composite Pre-transplant Metric” (188). The tool evaluates 
outcomes as a function of centers’ decision-making (i.e. transplant/delisting/waitlist 
mortality ratios) in addition to known patient and other factors (i.e. geography) relating to 
waitlist mortality (189–195). However, the tool’s intended use as a stand-alone (waitlist 
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only) center performance measure, and the plan not to report the results publicly or to 
incorporate results into reimbursement policies as with the current post-transplant 
Program Specific Reports, may limit its effectiveness at decreasing risk aversion. The 
extent to which implementation of Share 35 policy may have reversed the trends we 
observed is another important question to address in future research. 
 
Strengths & Limitations 
A major strength of the present study is the use of interrupted time series 
segmented regression analysis, a powerful tool and method of choice for policy 
evaluation (196). A limitation of this method, however, is the inability to adjust for 
potential time-varying confounding that may have affected the observed trends. However, 
exploration of the data revealed secular (gradual) changes in variable means over time, 
which would not explain the sudden jump observed in waitlist removal incidence at time 
of COP implementation. Furthermore, model estimates remained consistent after 
stratification on key variables. As information on center-level quality metrics is 
unavailable in the UNOS/SRTR database, we were unable to evaluate the role of poor 
performance. 
The UNOS/SRTR database used in this study has strengths and limitations 
common to administrative databases. Similar to other surgical datasets, data on patients 
evaluated but ultimately not considered surgical candidates (i.e. patients not waitlisted 
and follow-up data on patients removed from the waiting list) were either unavailable or 
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underreported. We would anticipate attenuation of our delisting trend estimates in the 
setting of such potential survivor bias (167), and we analyze mortality after waitlist 
removal conservatively. Accurate coding of “Reason for Removal” was reviewed using 
medical records at 4 tertiary care centers from 2002 to 2010, and underreporting of “too 
sick to transplant” and “medically unsuitable” by < 10% was shown (145). Such random 
misclassification would have attenuated our estimates of effect. Overall, the benefits of 
using this large, comprehensive, transplant-specific national database that includes over 2 
decades of data outweigh the potential limitations for this study. 
 
CONCLUSIONS 
We illustrate that implementation of CMS’s Conditions of Participation 
regulatory policy in 2007 was associated with an immediate, sharp increase in the 
likelihood of liver transplant candidate waitlist removal; this trend did not attenuate over 
the duration of the 5-year period after COP. Patients who could potentially benefit from 
liver transplantation are increasingly denied this life-saving procedure while post-
transplant survival did not significantly improve pre-post COP, resulting in a net 
population-level loss. 
Although the CMS Conditions of Participation policy (2007) was a quality 
initiative designed to improve patient outcomes, in reality, it failed to show beneficial 
effects for the liver transplant population overall. The National Organ Transplant Act, the 
Institute of Medicine, and the Final Rule consistently supported 3 goals: to increase 
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transplantation, to decrease waitlist mortality, and to maximize transplant benefit. 
However, this study illustrates that population benefit has declined since the 
implementation of COP.  
Future studies on understanding these trends and efforts to rebalance the waitlist-
transplant outcome scale are warranted, and this balance should be considered during 
development of future national policies and in clinical decision-making in order to better 
serve this patient population. 
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Table 2.1: Baseline* Characteristics of Patients on the Liver Transplant Waitlist, 
Scientific Registry of Transplant Recipients 2002–2012 (n = 90,765†) 
 Characteristic 
Pre-COP 
April 2002–June 2007, % 
(n = 51,038) 
Post-COP 
July 2007–December 2012, % 
(n = 52,971) 
Age in years 
  
< 45 20.1 16.7 
45–54 41.6 34.8 
55–64 30.0 38.4 
≥ 65 8.3 10.1 
Gender   
Men 61.8 61.1 
Women 38.2 38.9 
Race/ethnicity 
  
White 73.9 72.1 
Hispanic 13.9 14.8 
African American 7.8 8.3 
Insurance Status 
  
Private 63.4 60.8 
Medicare 16.1 19.1 
Medicaid 15.6 16.1 
Diabetes‡ 21.9 24.4 
Primary diagnosis 
  
Hepatitis C§ 37.4 35.9 
Alcoholic§ 16.9 18.5 
Cholestatic 8.8 8.2 
Acute hepatic necrosis 6.4 4.8 
Listing MELD 
  
< 15 56.2 48.6 
15–24 30.0 34.3 
25–34 8.3 10.5 
≥ 35 5.5 6.7 
Medical condition  
  
Home 85.7 82.4 
Hospitalized 8.5 11.3 
ICU 5.8 6.3 
*Baseline: Measured at time of initial waitlist registration. 
†13,244 patients present on the waiting list both pre- and post- COP; when randomly 
assigned to either category, all variables were significant at p < 0.001 except gender, 
which was significant at p < 0.05, after 5 repeat randomizations 
‡Types 1, 2, or unspecified 
§Primary diagnosis of “alcoholic cirrhosis with hepatitis C” were categorized under 
“Hepatitis C” 
 
COP, Centers for Medicare and Medicaid Conditions of Participation policy 
implementation (June 28, 2007); MELD, Model for End-Stage Liver Disease
31 
 
Table 2.2: Characteristics of Patients Removed from the Liver Transplant Waitlist Based 
on “Illness Severity”*, Scientific Registry of Transplant Recipients 2002–2012 (n = 
90,765) 
Characteristic 
“Too Sick to Transplant”* Transplanted  
Pre-COP 
 (n = 2,311) 
Post-COP 
(n = 4,340) p-value 
Pre-COP  
(n = 21,176) 
Post-COP  
(n = 20,528) p-value 
 
Percentage  Percentage  
Age in years† 
  
    
< 45 12.5 8.6  18.2 15.5  
45–54 33.9 25.4  40.4 31.4  
55–64 35.8 45.8  32.0 41.6  
≥ 65 17.8 20.2 < 0.001 9.4 11.5 < 0.001 
Women 40.8 41.9 0.38 34.0 36.0 < 0.001 
Race/ethnicity 
  
    
White 73.2 70.0  74.7 72.5  
Hispanic 15.0 16.8  12.3 12.9  
African American 7.8 8.6 0.05 9.0 10.2 < 0.001 
Insurance status 
  
    
Private 59.2 54.6  64.0 61.5  
Medicare 20.0 23.9  16.0 18.6  
Medicaid 15.6 17.3 < 0.001 14.8 15.6  
Diabetes (any type) 26.8 28.8 0.08 21.0 24.4 < 0.001 
Prior abdominal surgery 36.2 34.3 < 0.001 32.7 33.3 < 0.001 
Primary diagnosis 
  
    
Hepatitis C 36.1 37.0  36.7 35.2  
Alcoholic 16.0 17.0  15.6 16.6  
Cholestatic 8.2 7.3  9.5 8.4  
Acute hepatic necrosis 8.8 5.1 < 0.001 6.9 5.7 < 0.001 
Final MELD† 
  
    
< 15 26.3 20.5  23.5 16.7  
15–24 31.1 28.7  44.1 38.8  
25–34 18.6 20.2  20.0 26.5  
≥ 35 24.1 30.7 < 0.001 12.3 17.9 < 0.001 
Dialysis in prior week† 14.3 23.6 < 0.001 8.6 14.4 < 0.001 
Ascites† 
  
    
Slight 50.7 46.3  54.8 47.6  
Moderate 35.8 39.1 < 0.005 29.6 34.4 < 0.001 
Encephalopathy† 
  
    
Slight (1–2) 52.4 46.8  61.5 56.6  
Moderate (3–4) 30.9 33.1 < 0.001 13.0 13.9 < 0.001 
*Delisted for removal reasons “too sick” or “medically unsuitable”. 
†At time of waitlist removal 
 
COP, Centers for Medicare and Medicaid Conditions of Participation policy 
implementation (June 28, 2007); MELD, Model for End-Stage Liver Disease 
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Table 2.3: Effect of Centers for Medicare and Medicaid Conditions of Participation 
Policy Implementation on Rate of Waitlist Delisting Based on “Illness Severity”* and 1-
year Post-Transplant Mortality, Scientific Registry of Transplant Recipients 2002–2012 
(n = 76,733 candidates†; 34,603 transplants) 
Outcome Pre-COP Post-COP 
Incidence Rate  
Ratio 95% CI p-value 
“Too Sick” Waitlist Removal* 
 
 
  
Event, n removed 1,829 3,353    
Observation, person-quarters 256,148 263,162    
Level Change‖   1.16 1.12–1.20  < 0.001 
Trend Change‖   1.01 1.00–1.01 < 0.001 
      
Death < 1 Year After Transplant 
  
  
Event, n deaths 2,356 1,960    
Observation, liver transplants 17,630 16,973    
Level Change‖   0.99 0.94–1.04 0.62 
Trend Change‖   1.00 1.00–1.01 0.38 
      
*Delisted for removal reasons “too sick” or “medically unsuitable”. 
†Pre-COP, April 2003–June 2007 (n = 44,085 candidates); Post: July 2007–December 
2011 (n = 45,892 candidates). 
‡Observations (person-quarters), Model 1: number of candidates present on the waiting 
list, times number of quarters they were on the waiting list during each respective period; 
Model 2: number of transplants at any time during respective period.  
‖Level change represents change in the level of the quarterly incidence of the respective 
model outcome immediately after COP implementation (akin to a change in y-intercept). 
Trend change represents change in the slope, comparing post-COP slope to the projected 
pre-COP (historical) slope. Incidence rate ratio and 95% CI derived from exponentiated 
poisson model parameters. 
 
COP, Centers for Medicare and Medicaid Conditions of Participation policy 
implementation (June 28, 2007)
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Figure 2.1: Study inclusion/exclusion flow chart. Scientific Registry of Transplant 
Recipients 
 
aInactive if had fewer than 10 observations (# observations = sum of #candidates on 
waiting list in each quarter) per period or < 50 over entirety of study period 
bImbalance if < 6 quarters of data available immediately pre- or post-COP 
cDropped observations for one center with early gap in data (n = 45) 
dRandomly selected waitlist record for multi-listed patients at this point 
 
n, people; N, facilities; COP, Centers for Medicare and Medicaid Conditions of 
Participation policy implementation (June 28, 2007) 
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Figure 2.2: Change in the rate of liver transplant waitlist removal based on “illness 
severity” pre-post Centers for Medicare and Medicaid Conditions of Participation policy 
implementation, Scientific Registry of Transplant Recipients April 2002–December 2012 
(n = 90,765§) 
 
§Trends fitted* for study period used for regression modeling. Pre-COP trend line: April 
1, 2003–June 30, 2007(n = 44,085); Post-COP trend line: July 1, 2007–December 31, 
2011 (n = 45,892). 
*Pre/post trends, fitted 
**Projected pre-COP trend (referent) 
 
Results of regression model, comparing post-COP trend* to the referent pre-COP trend**, 
expressed as Incidence Rate Ratios: Difference in y-intercepts at the time of COP 
implementation: 1.16, 95%CI: 1.12–1.20 (p < 0.001); Difference in slopes: 1.01, 95%CI: 
1.00–1.01 (p < 0.001). 
 
COP, Centers for Medicare and Medicaid Conditions of Participation policy 
implementation (June 30, 2007)
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Figure 2.3: Trends in (A) mean Model for End-Stage Liver Disease (MELD), (C) age 
and (B) rate of patient removal from the liver transplant waitlist based on “illness 
severity,” stratified by MELD and (D) age, pre-post Conditions of Participation policy 
implementation, Scientific Registry of Transplant Recipients April 2002–December 2012 
(n = 90,765§) 
 
§718 people were missing data on final MELD score. 
*Final laboratory-based MELD score. Initial MELD mean versus time ran parallel to final 
MELD score. 
**Waitlist removals for reason “too sick” or “medically unsuitable” per 1000 waitlist 
candidates per quarter. 
 
COP, Centers for Medicare and Medicaid Conditions of Participation policy 
implementation (June 30, 2007); MELD, Model for End-Stage Liver Disease 
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Figure 2.4: Change in the incidence of death within 1-year of liver transplant, pre/post 
Centers for Medicare and Medicaid Conditions of Participation policy implementation, 
Scientific Registry of Transplant Recipients April 2002–December 2011 (n = 38,149 
transplants§) 
 
§Trends fitted* for study period used for regression modeling. Pre-COP, April 1, 2003–
June 30, 2007 (n = 17,630 transplants); post-COP: July 1, 2007 – December 31, 2011 (n 
= 16,973 transplants). 
*Pre/post trends, fitted 
**Projected pre-COP trend (referent) 
Results of regression model, comparing post-COP trend* to the referent pre-COP trend**, 
expressed as Incidence Rate Ratios: Difference in y-intercepts at the time of COP 
implementation: 0.99, 95%CI: 0.94–1.04 (p = 0.62); Difference in slopes: 1.00, 95%CI: 
1.00–1.01 (p = 0.38) 
 
COP, Centers for Medicare and Medicaid Conditions of Participation policy 
implementation (June 30, 2007) 
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CHAPTER III 
ASSOCIATION BETWEEN FUNCTIONAL STATUS AND SARCOPENIA IN 
LIVER TRANSPLANT PATIENTS 
38 
 
ABSTRACT 
Background: There is a growing body of evidence that frailty and functional 
performance independently predict liver transplant outcomes. The Karnofsky 
Performance Status (KPS) scale is the United Network of Organ Sharing assessment tool 
of choice for measuring transplant center case-mix. Its utility for liver transplant patients 
is unknown. The purpose of this study is to explore the relationship between provider-
assessed KPS and objective, validated markers of frailty (sarcopenia). 
Methods: This observational study includes 136 adult, first-time liver transplant 
recipients at UMass Memorial (2006–2015) that had two abdominal CTs available: (1) ≤ 
90 days pre-transplant, and (2) ≥ 7 days before (1). We used psoas muscle size and 
quality measures to explore sarcopenia pre-transplant, as a relative change and as a rate 
of muscle wasting. We used correlation and logistic regression to examine the 
relationship between sarcopenia and KPS.  
Results: The mean age was 55 years and last laboratory-calculated MELD was 22; 34% 
were women. Half was sarcopenic pre-transplant, and 71.3% declined in lean psoas area 
(LPA) at an average rate of 11% per month. Functional impairment was present in 86%. 
Compared to subjects with minimal or no evidence of sarcopenia on CT scan, subjects 
who experienced muscle wasting at a rate of ≥ 1% per month had 2.83 times the risk 
(95% confidence interval (CI): 1.18–6.80) of being severely impaired, disabled and/or 
moribund pre-transplant (adjusted for age, gender and race). This risk increased by 2.32 
(CI: 1.44–3.75) times for every standard deviation decrease in pre-transplant LPA. 
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Conclusions: Provider-assessed physical health status is moderately correlated with 
objective measures of frailty. More research on the utility of using either or both 
measures in prognostication and management of high-risk liver transplant patients is 
warranted.
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INTRODUCTION 
The growing shortage in liver donation in the U.S. has transformed practice 
patterns in liver transplantation over the last decade (197). To minimize mortality on the 
waiting list, the current system of liver allocation was designed to prioritize the “sickest 
first.” Patients are ranked according to the Model for End-Stage Liver Disease (MELD) 
score, which is calculated using 3 objective laboratory values (creatinine, bilirubin, and 
international normalized ratio). Although MELD is a reliable predictor of 3-month 
waitlist mortality at the population level, it is a poor predictor of post-transplant mortality 
(19,25,26,198). Recent studies have shown that MELD score underestimates the risk of 
waitlist and post-operative mortality among liver transplant patients who are considered 
to be “frail” (25,30,31). It is hypothesized that frailty may make patients more vulnerable 
to stressors such as surgery due to limited physiologic reserve, leading to worse outcomes 
when faced with a stressor such as major abdominal surgery (30,32). 
Frailty syndrome describes a dynamic and potentially modifiable phenomenon of 
decreasing strength, function, and overall health status as a result of advanced age, 
chronic disease and malnutrition, comorbidities and other systemic dysfunctions 
(85,86,104,108,136). Muscle wasting, or sarcopenia, is a hallmark of end-stage liver 
disease and has been used as an objective measure of frailty and predictor of morbidity 
and mortality in this population (34,35,38,40–67). However, assessment of sarcopenia or 
other objective measures of frailty proposed have limited clinical utility since they are 
often not practical to assess in the perioperative setting. Moreover, this measure may be 
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too narrow to describe global physical health status (42) compared with a phenotypic, 
clinician-assigned, score on a validated scale of frailty (34). 
Decrease in muscle mass due to reductions in muscle fiber number and size as 
well as strength lead to declines in functional performance (68–71). Functional status has 
also been shown to independently predict liver transplant outcomes (32,129,199–201). In 
accordance with a UNOS/OPTN mandate, functional status data have been collected 
from all U.S. transplant centers using the Karnofsky Performance Status (KPS) scale for 
more than a decade. These data are then used to risk-adjust for center case-mix in the 
creation of Program Specific Reports on outcomes. Though the KPS is a widely validated 
tool for assessment of global physical function across many disease indications and has 
been used clinically and in clinical trials for over 60 years (51,64,66,67,101,114,131,201–
218), its validity in a liver transplant population remains unknown. While analytic 
morphomics research has been used to identify a strong correlation between objective 
measures of sarcopenia and global assessments of physical health status, the study was 
conducted in a population of older (> 70 years) general surgical patients and not liver 
transplant patients (219). There remains a gap in the literature on defining and 
understanding the mechanisms underlying the frailty phenotype for liver transplant 
patients. This will be the first study to describe the relationship between phenotypic and 
physiologic signs and symptoms of frailty syndrome in a liver transplant population. 
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The aim of this study is to describe the relationship between provider-assessed 
functional status (KPS) and objective measures of sarcopenia, collected using validated 
analytic morphomics methodology. 
 
MATERIALS & METHODS 
 
Study Design and Population 
This retrospective cohort study includes adults who underwent first-time liver 
transplantation at UMass Memorial Healthcare Center (UMMHC) between January 1, 
2006, and October 31, 2015. UMMHC is a 781-bed, tertiary care medical center located 
in Worcester, Massachusetts, U.S. The UMMHC transplant program includes adult and 
pediatric liver, kidney, and pancreas transplants. In 2012, this center transplanted more 
livers than any other program in New England (220). Patients without both a “pre-
transplant” (≤ 90 days before transplant) abdominal computed tomography (CT) scan (n 
= 228) and a referent (“baseline”) CT scan at least 7 days prior to pre-transplant CT (n = 
28), or patients that were missing data on functional status at transplant (n = 3) were 
excluded (Figure 3.1). 
 
Data Collection and Variable Definitions 
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Muscle Measures 
Muscle measurements were collected from CT scans performed as part of routine 
clinical care. Patients on the UMMHC liver transplant waitlist undergo routine abdominal 
imaging at the time of candidacy evaluation and every 6–12 months until transplant, 
depending on their primary diagnosis. Baseline and pre-transplant psoas muscle size 
(cross-sectional area, mm2) and quality (density, Hounsfield units (Hu)) for both left and 
right psoas muscles were measured at the L4 vertebral level superior plate according to 
Analytic Morphomics methodology (43). All measures were collected by a UMass 
radiology attending physician with fellowship training in abdominal radiology (AS) using 
tools built into the radiology management system (General Electric (GE) CentricityTM 
Radiology Information System /Picture Archiving and Communication System (PACS)). 
Intra-rater reliability was confirmed using Test-Retest methodology prior to initiation of 
study data collection (see Appendix 3A for details) (221). 
Individual psoas muscle measurements were combined to create the following 
variables: Total Psoas Area (LPA) (left + right cross-sectional area, mm2), mean density 
((left + right density)/2, Hu), Lean Psoas Area (LPA) (TPA x (mean density+85/) 170), 
mm2) and stature-normalized(49) LPA (LPA/height2, mm2/m2) for each time point. These 
measures were explored in the following ways: 1) Sarcopenia pre-transplant: pre-
transplant LPA relative to “normal,” 2) Relative Sarcopenia, or, extent of muscle 
wasting: relative LPA change from baseline, and 3) Muscle wasting rate: rate of relative 
change per month. Normal in (1) was defined using gender-specific LPA averages 
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reported in a sample of over 1,200 elective surgery patients (222) and assessed at a single 
time point (pre-transplant) sarcopenia (Sarcopenic/Not Sarcopenic: > 1 standard 
deviation below average/≤ 1 standard deviation above average; cut points: 1,488.4 mm2 
for men, 974.8 mm2 for women). Cut-points were used to facilitate comparability with 
other studies. Relative sarcopenia uses patients’ own “baseline” (psoas measures from 
earliest available abdominal CT scan) as the referent: Paper-transplant-LPAbaseline /LPAbaseline 
(%). Because this was a retrospective study, time between scans was not uniform among 
subjects. We therefore standardized relative change in LPA per the number of months 
between CT scans (%/month). Relative change variables are explored as both continuous 
variables and grouped into tertiles. 
 
Functional Status 
Functional status was defined using the Karnofsky Performance Status scale, 
which is described in Table 1.1. The KPS scale was designed to be assessed by providers 
and has been widely used and validated in many different populations, including patients 
with end-stage renal disease (51,64,66,67,101,114,131,201–218). The original KPS is an 
11-tiered scale, decreasing from a maximum of “100%: normal, no complaints, no 
evidence of disease” to “0%: Dead,” in 10% increments. A collapsed, 3-tiered version is 
also available and has high inter-rater reliability (201,202,210). We assigned labels to 
summarize extent of functional impairment/disability in each respective category as 
follows: None/Normal function (A: 80–100%), Moderate limitations (B: 50–70%), 
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Severely impaired disabled (C: ≤ 40%). We explore the KPS as a continuous, categorical, 
and as a binary variable. 
 
Covariates of Interest 
Potential confounders of interest were selected based on literature review and a 
priori knowledge. Characteristics of interest included sociodemographics, body habitus, 
comorbidities, liver diagnoses, and illness severity (laboratory-based MELD scores, 
Child-Pugh scores, sequelae of liver disease, medical condition). As previous studies 
have shown substantial differences in degree and mechanism of muscle wasting in men 
versus women, gender was a key characteristic that we explore in the most depth.  
These data were collected from the UMMHC transplant registry, which includes 
variables collected and submitted by mandate to UNOS/SRTR database and other clinical 
and laboratory variables from patients’ electronic medical records that are auto-imported 
into the registry in real-time. 
 
Data analysis 
Univariate and bivariate distributions of muscle measures, functional status, and 
key characteristics at baseline and pre-transplant were explored graphically and with 
contingency table analyses. Descriptive statistics for the study sample are presented as 
follows: Continuous variables are described as mean (standard deviation (SD)) if 
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normally distributed and median (interquartile (IQR)) range if skewed; categorical 
variables are described as proportions (%).  
The relationship between sarcopenia and functional status was assessed using 
correlation and logistic regression analyses. Correlation between continuous KPS and 
LPA rate of change was compared using Spearman’s rho (rs) rank correlation coefficient 
for ordinal data (223). Testing correlation assumptions revealed a parabolic relationship 
between variables, with an inflection point at 20% increase in LPA per month; therefore, 
we report correlations for subjects with values of less than +20%, excluding 5 people (see 
Appendix 3B for details). Power calculations for minimum detectable effect size are 
described in Appendix 3C. 
We evaluated unadjusted and adjusted odds of severe functional impairment (KPS 
10–40% versus referent, 50–100%) for 3 working definitions of muscle wasting: 1) rate 
of muscle wasting, 2) pre-transplant sarcopenia (yes/no), and 3) pre-transplant LPA (per 
SD decrease), using logistic regression and adjusting for age (≥ 55/< 55 years), gender 
(women/men), and race (white/non-white ethnicity). Results are presented as odds ratios 
(OR) with accompanying 95% confidence intervals (CI). 
Tests of statistical significance were selected as appropriate based on normality of 
the dependent variable (please see Appendix 3D for details); p-values ≤ 0.050 were 
considered significant. All analyses were conducted using Stata version 13 (StataCorp 
LP, College Station, TX). This study was approved by the UMass Medical School 
Institutional Review Board. 
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RESULTS 
The final study sample included 136 patients who underwent first-time liver 
transplantation between 2006 and 2015. Descriptive statistics for the overall study sample 
are listed in Supplemental Table 3.1 and summarized here. The mean age was 55.4 years, 
33.8% were women, and the most common ethnic minority was Hispanic/Latino (14.7%); 
77.2% of the sample was white. The most prevalent primary etiology of liver disease was 
hepatitis C/viral hepatitis (47.1%), and hepatocellular carcinoma was present in 36.0% of 
the sample. The mean laboratory-calculated MELD score pre-transplant was 22.3, and the 
majority (68.4%) of the sample was in the worst Child-Pugh class (C) for cirrhosis 
severity. The median (interquartile range (IQR)) waitlist time was 3.2 (0.8–12.4) months. 
 
Muscle wasting and recipient characteristics 
Table 3.1 includes descriptive statistics of the sample according to the presence or 
absence of sarcopenia on pre-transplant CT (in relation to gender-specific thresholds of 
“normal” lean psoas area (LPA)). Patients with sarcopenia were 5 years older on average, 
and weighed an average of 20 pounds less, and were twice as likely to have been 
previously diagnosed with diabetes than patients who did not have sarcopenia. Alcoholic 
hepatitis was a more common primary etiology (29.9% versus 18.8%) and hepatocellular 
carcinoma was less likely among patients with sarcopenia. Sarcopenic patients’ disease 
was more severe according to pre-transplant MELD score, labs, and hospitalization status 
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(31.3% vs. 11.6% ICU); three-quarters of the patients with sarcopenia were classified in 
Child-Pugh class C. 
Table 3.2 summarizes changes in psoas muscle measures by gender and 
Supplemental Table 3.2 displays more detail. The majority of the sample declined in 
either muscle size or density (86.8%). Approximately three-quarters of the sample lost 
total psoas area (TPA) and slightly over half declined in muscle quality (55.2%); 71.3% 
declined in lean psoas area (LPA) from baseline to pre-transplant CT overall (average 
time between scans: 12 (IQR: 3.6–36.5) months). The mean (SD) relative change in LPA 
was -10.7 (19.9) % and the average rate of relative change was -0.5% per month (-1.5 to -
0.04% per month). 
While total psoas area (TPA) and density changed significantly from baseline to 
pre-transplant in the overall sample, women only lost a median of 2.9% of baseline TPA 
compared with 12.6% among men. In contrast, women significantly declined in muscle 
quality (-10.0%, p = 0.03) while men did not (-1.5%, p = 0.20). A significant difference 
persisted even after accounting for density in LPA. However, normalizing relative LPA 
change for time (months) between CT scans equalized differences by muscle wasting by 
gender (p = 0.07).  
Table 3.3 shows recipient characteristics by tertiles of rate of LPA loss (% LPA 
lost per month between CT scans) and Supplemental Table 3.3 shows characteristics by 
tertiles of relative LPA loss (%). By tertile of LPA loss rate, in order of increasing 
severity, the median (IQR) change in LPA was 7% (2 to 13%), -14% (-26 to -6%), and -
49 
 
22% (-32 to -12%). Characteristics associated with more rapid rates of LPA loss included 
higher rate of weight loss per month on the waitlist, higher MELD score at registration 
and pre-transplant, with worse bilirubin and coagulation labs, and more critical medical 
condition (Table 3.3). Patients with higher rates of muscle wasting were less likely to 
have hepatocellular carcinoma. 
 
Sarcopenia and Functional Status 
Functional impairment (moderate or severe physical limitations per KPS) was 
present in 86.0% (n = 117) of the sample at transplant. The mean KPS score was 47.3% 
and one-third (31.6%) of the sample had a KPS of 20%. KPS distributions did not vary 
by gender (p = 0.92). 
Figure 3.2 illustrates the relationship between continuous functional status and 
rate of LPA loss. A moderate correlation was identified (rs = 0.31; p < 0.001). 
Supplemental Table 3.5 shows the correlations stratified by recipient characteristics of 
interest, with average LPA rates displayed for each category of functional status. 
Table 3.4 shows the results of logistic regression models for severe functional 
impairment/disability by 3 different measures of muscle wasting. Severe 
impairment/disability was more common among subjects with higher rates of muscle 
wasting, and among those who were sarcopenic pre-transplant. Mean LPA among 
severely impaired subjects was 1,215.4 mm2 compared with 1,473.9 mm2 for subjects 
who were of Moderate or Normal functional status (p = 0.001).  
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Compared to subjects with minimal or no evidence of sarcopenia on CT scan, 
subjects who experienced muscle wasting at a rate of ≥ 1% per month had 2.83 times the 
risk (95% confidence interval (CI): 1.18–6.80) of being severely impaired, disabled 
and/or moribund pre-transplant (adjusted for age, gender and race). The adjusted odds 
ratio observed for subjects with pre-transplant sarcopenia compared with those without 
was similar (2.67; CI: 1.29–5.52). The odds of severe functional impairment/disability 
more than doubles for each standard deviation decrease in lean muscle size on pre-
transplant CT (2.32; CI: 1.44–3.75). 
 
DISCUSSION 
We present results from the first study to evaluate the relationship between 
Karnofsky Performance Status scale and objective measures of frailty (sarcopenia) in a 
liver transplant population. The mean age of the sample was 55 years, last laboratory-
calculated MELD was 22.3, and hepatitis C was the most prevalent etiology of liver 
disease. Prevalence of muscle wasting (loss in psoas area or density compared to 
“baseline” CT) and prevalence of functional impairment (KPS ≤ 70%) pre-transplant 
were almost identical (86.8 versus 86.0%, respectively). Pre-transplant sarcopenia, 
defined relative to average in a general surgery population, was present in about half of 
the sample. 
The prevalence of sarcopenia we report is consistent with that reported in other 
studies of liver transplant patients (41% (65), 45%(49)). We observed differences 
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between men and women in terms of the type of muscle wasting subjects experienced 
(size (total area) for men versus quality (density) for women) and these findings are 
supported in earlier literature (43,47,49,65,222). We also report a new finding: after 
accounting for changes in density, relative change from baseline as a percent, and months 
over which the changes occurred, degree of muscle wasting was no longer statistically 
different for men and women (p = 0.07).  
Compared with a study that examined change in psoas muscle perioperatively (90 
days pre or post) in a cohort of general and major vascular surgery patients, we showed a 
similar but smaller proportion of patients who declined TPA in our study (73%) 
compared to theirs (83%) (224). This minor difference could be explained by the period 
of observation: the body goes through a rollercoaster of physiologic changes in 
recovering from major surgery, and trunk muscle size may substantially decline for 
bedbound patients with postoperative complications from not only misuse but 
physiologic stress (e.g. infection). Perioperative change in psoas muscle has been shown 
to independently predict mortality among cirrhotics undergoing transjugular intrahepatic 
portosystemic shunt procedures (139). For these reasons, we did not include CT scans 
performed within 90 days post-transplant, as the aforementioned postoperative setting is 
generally very intensive but also variable for liver transplant patients. 
We found that functional status was associated with sarcopenia on pre-transplant 
CT as well as with change in muscle mass and/or quality (loss of lean psoas area). Our 
findings are supported by results of studies of sarcopenia in general surgery patients at 
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University of Michigan (219,222). In one study of patients aged 70 and over who were 
admitted for general surgery procedures, 42% exhibited functional impairment on in-
clinic assessment of physical function (e.g. walk test) and only 22% reported difficulty 
with activities of daily living (219). The prevalence of functional impairment in this 
population was substantially lower than in our sample of 136 liver transplant recipients 
(86.0%). Despite these differences, the estimates of effect that the authors found for total 
psoas area in relation to difficulties performing instrumental activities of daily living 
(ADLs) were almost identical to findings in our study (OR 0.53 per SD of TPA versus 
OR 0.55 per SD increase in LPA (or TPA) pre-transplant (note that these results are 
currently presented in Table 3.4 as the inverse: OR 1.83 per SD decrease). We also 
showed that muscle wasting of as little as 1% per month is associated with an almost 
three-fold higher risk of severe functional impairment, compared to patients with no sign 
of muscle wasting and after adjusting for age, gender, and race (OR 2.83 CI: 1.18–6.80). 
 
Implications of Results 
UNOS/SRTR replaced the previously collected activities of daily living (ADL) as 
the primary measure of functional status with the Karnofsky Performance Status (KPS) 
around 2005. However, the Liver and Intestinal Transplant Committee of OPTN recently 
asked that research on using KPS nationally be pursued, as there is concern in the 
transplant community about whether it is appropriate to risk-adjust centers’ outcomes for 
case-mix using a variable that has not been validated in a liver transplant population 
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specifically (218). This study found moderate correlations between provider-assessed 
KPS and objective markers of frailty but more research is warranted. 
Interventions that may slow frailty and sarcopenia progression, such as nutritional 
supplementation and strength/resistance muscle training, have been hypothesized across 
many populations (54–57,60–62,137–139,225). The concept of “frailty syndrome” 
originates from a geriatric framework and describes a dynamic and potentially modifiable 
phenomenon of decreasing strength, function, and overall health status as a result of 
advanced age, chronic disease and malnutrition, comorbidities and other systemic 
dysfunctions (85,86,104,108,136). Although many of the definitions and objective 
measures of frailty that were developed in non-transplant populations have been widely 
validated (125), there are important differences in these populations that limit their direct 
translation to liver transplant patients. 
Whereas age was originally conceptualized as the primary driver of frailty among 
geriatric populations, and cachexia, an irreversible progressive inflammation-based is the 
driver of frailty in oncology populations, it is actually “secondary sarcopenia,” due to 
chronic disease, malnutrition, and endocrine abnormalities (79), that drives frailty in end-
stage liver disease. This has important implications for both designing potential 
interventions and for prognostic indications of sarcopenia in liver transplant patients 
compared to other populations. 
As the underlying etiologies of frailty are hypothesized to vary across the 
different groups in which sarcopenia has been recognized as a strong predictive variable 
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for outcomes, interventions may also need to target different deficits or approach the 
deficits from different angles. Nutritional supplementation has been studied in liver 
disease and it has been shown that meal-induced albumin synthesis is impaired even in 
compensated cirrhotic patients (226) and may be insufficient to overcome underlying 
endocrine abnormalities. 
Furthermore, disease courses and prognoses in aged versus cirrhosis populations 
differ dramatically. In the original populations where frailty is described, frailty is 
conceptualized as progressive and mostly irreversible. This is in contrast to a liver disease 
population, which may have some, or potentially all, of these processes reversed after 
replacing the non-functioning organ with a new, non-diseased organ. We call for further 
research on understanding whether and which preventive measures, or, “prehabilitation” 
interventions, some thus far shown to be effective in other types of major surgeries such 
as cardiac surgery, may be needed in a liver transplant population. Although the literature 
has shown that sarcopenia predicts mortality, functional status predicts mortality, and 
now we add that functional status maps onto objective measures of sarcopenia 
adequately, none of these associations are necessarily linked directly to outcomes as 
causal. In other words, sarcopenia may simply be a proxy for describing global health 
status of the patient. Intervening to improve muscle mass directly through physical 
training and protein supplementation may not bear meaningful effects on improving 
outcomes as for cardiac surgery patients, who do not suddenly recover muscle satellite 
cell generation after surgery the way that transplant patients recover protein metabolism 
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with a new organ, but recover slowly through cardiac rehabilitation therapy involving 
exercise. 
 
Strengths & Limitations 
This work must be considered in the context of its limitations. The primary 
limitation of this study is the relatively small sample size. This limited the number and 
types of analyses we were sufficiently powered to conduct. A potential limitation of using 
single-center data is generalizability of findings. To address generalizability of measures, 
we evaluated sarcopenia variable definitions using a referent from previously published 
averages in a general surgery population and used percent of loss for within-patient 
changes. A limitation to the averages we used as “normal,” however, is that although 
elective general surgery patients may be healthier than the average liver transplant patient 
overall, they are likely sicker than a general healthy population such as from trauma 
patients and may too be suffering from sarcopenia, perhaps due to other etiologies 
(cancer, advanced age). This limitation is inherent to the literature available thus far, and 
we call for further research describing general population prevalence and definition of 
“normal” for analytic morphomics methods, which measure psoas at the L4 level 
specifically and for which no referent values are published. However, the use of single-
center data is also a strength for this retrospective study, as KPS assessment protocols 
and patient population norms are likely to be more consistent and more homogenous 
within a single transplant center than between centers. 
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A major but unavoidable limitation to the study is the retrospective design of the 
study, which introduced potential selection bias. There was potential for survivor bias by 
including only transplant recipients rather than all waitlist candidates. In contrast, the 
sample may have been biased toward sicker patients if sicker patients are likely to 
undergo more frequent abdominal CT scans. We compared characteristics among patients 
excluded versus included and found some indication that excluded patients were less 
sick. However, the primary outcome variable, functional status, was not significantly 
different between groups. As sarcopenia and muscle wasting were associated with 
cirrhosis severity, it is possible that our results are exaggerated by focusing on a subset of 
sicker patients. The retrospective design also meant we were also likely unable to capture 
true “baseline” psoas muscle measures.  
This study was innovative in its approach by focusing on clinical translation of 
our process and results: we worked with an MD Radiologist with fellowship training in 
abdominal imaging to collect data in real-time. In contrast, most research studies on 
sarcopenia rely on expensive and technically sophisticated Matlab engineering/image 
processing software to collect and interpret data. While having a single rater for psoas 
muscle measures could be a limitation, the very high level of technical expertise and high 
agreement between measures (97%) on assessment of intra-rater reliability virtually 
eliminate this potential threat to validity. We defined the primary variables, specifically 
“sarcopenia” and functional status, using universally available cut-points or relative to the 
patient’s own baseline rather than only reporting tertiles within our unique population, 
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which may not necessarily translate to another center or for assessing an individual 
patient. 
 
CONCLUSIONS 
The results of this study show a moderate correlation between clinically evident 
functional impairment/disability, assessed by providers, using the Karnofsky 
Performance Status scale, and sarcopenia, an objective marker of frailty syndrome that 
can be measured on abdominal CT scan. Both the extent and rate of muscle wasting were 
significantly associated with pre-transplant functional status on regression modeling, 
increasing risks of severe functional impairment/disability by 2–3-fold after adjustment 
for age, gender and race. However, if sarcopenia were a direct objective representation of 
clinical functional status, the correlation coefficients and odds ratios would be many 
times greater than we observed. We hypothesize that sarcopenia and functional status 
likely measure different aspects of liver failure and that global health status in liver 
transplant patients may be affected by an array of heterogeneous disease manifestations 
that we were unable to dissect due to limited sample size. More research on the utility of 
using either or both measures in prognostication and management of high-risk liver 
transplant patients is warranted. Better understanding and characterization of frailty 
syndrome in liver transplant patients holds great potential for improving clinical care and 
informing decision-making for patients on the transplant waitlist.  
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Table 3.1: Pre-transplant characteristics of subjects that underwent liver transplantation 
at UMass Memorial 2006–2015, by category of sarcopenic versus not sarcopenic on pre-
transplant CT (n = 136) 
 Sarcopenia, pre-transplant† 
Characteristic* 
> 1 SD below normal 
(n = 67) 
Within normal limits 
(n = 69) 
Age ≥ 55 years 70.2 46.4 
Women 34.3 33.3 
Ethnic minority 25.4 20.3 
Primary insurance   
Private 43.3 34.8 
Public-Medicaida 26.9 42.0 
Public-Medicare 29.9 23.2 
Body Mass Index, kg/m2 27.0 (5.5) 29.3 (5.6) 
Weight, kg 77.6 (19.3) 86.2 (19.1) 
Height, m 1.69 (0.1) 1.71 (0.1) 
Diabetesb 34.3 14.5 
Primary Cause of Liver Disease    
Hepatitis C and similar infections 38.8 55.1 
Alcoholic Hepatitis 29.9 18.8 
Other liver diseases 31.3 26.1 
Hepatocellular Carcinoma 29.9 42.0 
Child-Pugh class   
A (mild) 4.5 10.1 
B (moderate) 19.4 29.0 
C (severe) 76.1 60.9 
Waitlist time, months 2.2 (0.6–11.1) 3.6 (1.0–13.0) 
MELD score (laboratory) 24 (16–34) 17 (12–27) 
< 15 19.4 43.5 
15–29 44.8 34.8 
≥ 30 35.8 21.7 
Creatinine 2.1 (1.8) 1.5 (1.4) 
Total bilirubin 9.4 (10.9) 8.5 (11.5) 
International Normalized Ratio 2.0 (1.4) 2.0 (2.0) 
Albumin 3.0 (0.7) 3.0 (1.0) 
Medical Condition   
Hospitalized 25.4 27.5 
ICU 31.3 11.6 
Life support 17.9 5.8 
Psoas muscle density, Hu 36.1 (7.6) 43.4 (8.9) 
Total psoas area, mm2 1,442 (376.9) 2,212.3 (491.1) 
*Column percent, mean (standard deviation), or median (interquartile range) 
†Lean psoas area on pre-transplant (≤ 90 days) abdominal CT that is > 1 standard 
deviation below gender-specific averages (cut-points: men: 1,488.4 mm2; women: 974.8 
mm2) reported in a study of 1,279 patients admitted for elective general surgery 
procedures from 2006–2011 at University of Michigan (Kirk PS, et al 2015). 
aIncludes 1 person with insurance type - other 
bDiabetes types 1, 2, or unspecified 
Kg: kilograms; KPS: Karnofsky Performance Status; m: meters; MELD: Model for 
End-Stage Liver Disease; n: number 
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Table 3.2: Changes in psoas muscle measures from baseline to pre-transplant CT, by 
gender, UMass liver transplant recipients 2006–2015 (n = 136) 
Relative Change, %* 
Men 
(n = 90) 
Women 
(n = 46) 
 
 
∆ Total Psoas Areaa 
-11.3 
(-21.1 to -0.7) 
-2.9 
(-16.7 to 8.9) 
∆ Densityb 
-1.5  
(-20.2 to 12.0) 
-10.0  
(-24.5 to 16.6) 
∆ Lean Psoas Areac 
-10.9 
(-25.3 to -1.0) 
-3.4 
(-20.3 to 6.4) 
∆ Lean Psoas Area/monthd 
-0.5  
(-1.4 to -0.1) 
-0.1 
(-1.6 to 0.8) 
   
*% = (Pre-transplant – baseline) / baseline, median (interquartile range) 
aTotal psoas area = left + right psoas, mm2 
bDensity = Mean density of left and right psoas, Hounsfield units 
cTotal psoas area x Density adjustment factor 
dPer month between CT scans; median (interquartile range) values for men: 11.6 (4.7–
41.4) months, women: 13.0 (1.4–33.7) months (p = 0.30). 
 
CT: Computed tomography scan; n: number in group; p: probability.
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Table 3.3: Characteristics in relation to rate of change of lean psoas area (tertiles),  
UMass liver transplant recipients 2006‒2015 (n = 136) 
*Column percent, mean (standard deviation), or median (interquartile range) 
†Tertile categories, %/month; Severe/Moderate/None: n = 46/45/45 
aDiabetes types 1, 2, or unspecified 
bLaboratory calculated MELD score 
 
Kg: kilograms; m: meters; MELD: Model for End-Stage Liver Disease; n: number
 
Tertiles of Rates of Change in Lean Psoas Area over Baseline† 
 
Highest Moderate Minimal/No loss 
Median (range), %/month: -2.75 (-57.92 to -1.02) -0.45 (-0.95 to -0.09) 1.13 (-0.06 to 79.08) 
Time between CT scans, months: 6.8 (2.7–13.0) 37.6 (16.6–64.8) 8.7 (1.8–35.2) 
Characteristic* 
 
  
Age ≥ 55 years 56.5 62.2 55.6 
Women 30.4 20.0 51.1 
Ethnic minority 17.4 26.7 24.4 
Public health insurance  56.5 66.7 60.0 
Body Mass Index, kg/m2 24.5 (4.9) 29.0 (5.1) 28.1 (6.8) 
Weight, kg 81.2 (19.1) 85.4 (16.7) 79.3 (22.5) 
Height, m 1.71 (0.1) 1.71 (0.1) 1.67 (0.1) 
Diabetesa 21.7 35.6 15.6 
Primary Cause of Liver Disease     
Hepatitis C/viral-other 45.7 53.3 42.2 
Alcoholic Hepatitis 23.9 24.4 24.4 
Other liver diseases 30.4 22.2 33.3 
Hepatocellular Carcinoma 21.7 44.4 42.2 
Time on waiting list, months 1.7 (0.5–6.1) 6.4 (1.5–15.5) 3.0 (0.8–13.9) 
Weight loss per month on waitlist    
< 0‒≤ 5% 28.3 57.8 45.5 
> 5% 26.1 8.9 25.0 
MELD at registrationb 22 (12–29) 14 (10–20) 15 (10–20) 
MELD pre-transplantb 29 (20–38) 19 (12–24) 16 (12–25) 
Creatinine 1.4 (0.9–2.4) 1.0 (0.8–1.6) 1.1 (0.8–2.1) 
Total bilirubin 11.1 (3.5–19) 3.0 (1.5–6.1) 3.1 (1.4–6.3) 
International Normalized Ratio 2.0 (1.4–2.6) 1.5 (1.2–1.9) 1.4 (1.2–1.8) 
Albumin 2.9 (2.7–3.3) 2.8 (2.5–3.5) 3.0 (2.4–3.4) 
Child Pugh    
B 17.4 24.4 31.1 
C 80.4 62.2 62.2 
Portal Vein Thrombosis 17.4 15.6 13.3 
Medical condition    
Not Hospitalized 32.6 57.8 66.7 
Hospitalized, not ICU 32.6 26.7 20.0 
ICU 34.8 15.6 13.3 
Life support 21.7 6.7 6.7 
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Table 3.4: Unadjusted and adjusted odds ratios (95% CIs) for severe functional 
impairment/disability by rate of muscle wasting, pre-transplant sarcopenia, and decrease 
in lean psoas area, UMass liver transplant recipients 2006–2015 (n = 136) 
 
Severe impairment/disability† 
 % Impaired Unadjusted Adjusteda 
Rate of muscle wastingb 
   
High 56.5 2.60 (1.11–6.09) 2.83 (1.18–6.80) 
Moderate 46.7 1.75 (0.75–4.11) 1.84 (0.75–4.51) 
Minimal/None 33.3 Referent Referent 
Sarcopenic pre-transplantc 
   
> 1 SD below normal 56.7 2.46 (1.23–4.91) 2.67 (1.29–5.52) 
Within normal limits 34.8 Referent Referent 
Lean Psoas Area pre-transplantd   
Per standard deviation unit 
decrease 
 
1.83 (1.24–2.69) 2.32 (1.44–3.75) 
†Karnofsky Performance Status, 10–40% versus 50–100% (referent) 
aAdjusted for age (≥ 55/< 55 years), gender and race (white/non-white). 
bTertiles of relative loss in lean psoas area per month, High: ≥ 1% loss/month; Moderate: 
< 1%–0.1% loss/month; Minimal/None: < 0.1% or increase in lean psoas area 
cLean psoas area on pre-transplant (≤ 90 days) abdominal CT that is > 1 standard 
deviation below gender-specific averages (cut-points: men: 1,488.4 mm2; women: 974.8 
mm2) reported in a study of 1,279 patients admitted for elective general surgery 
procedures from 2006–2011 at University of Michigan (Kirk PS, et al 2015). 
dDecrease relative to sample distribution at single pre-transplant time point 
 
CI: confidence interval. n: number in group.
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Figure 3.1: Study inclusion/exclusion flow chart 
 
 
*Abdominal CT ≤ 90 days before transplant 
**Abdominal CT at least 7 days before pre-transplant CT
Starting Patient Population 
Adults who underwent liver transplantation at UMass Memorial Healthcare Center 
January 1, 2006 – October 31, 2015 
(n = 402) 
Final Study Sample 
(n = 136) 
Retransplants (n = 7) 
No pre-transplant CT* (n = 228) 
No baseline CT** (n = 28) 
No functional status data (n = 3) 
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Figure 3.2: Correlation between pre-transplant functional status and rate of change in 
Lean Psoas Area from baseline to pre-transplant, UMass liver transplant recipients 
2006‒2015 (n = 131) 
 
 
*Correlations were assessed using spearman’s rho for rank-order correlation between 10-
point Karnofsky Performance Status scale and continuous sarcopenia and restricted to the 
range of lean psoas area values for which test assumptions were not violated: below (+) 
20% increase in the rate of relative Lean Psoas Area change/month (see appendix 3B for 
further detail on this determination). 
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CHAPTER IV 
IMPACT OF RECIPIENT FUNCTIONAL STATUS ON LIVER TRANSPLANT 
OUTCOMES 
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ABSTRACT 
Background: Program Specific Reports attempt to risk-adjust outcomes for transplant 
centers' unique case-mix by including a global measure of physical health status in their 
liver transplant survival models, the Karnofsky Performance Status (KPS) scale. 
Although the KPS scale has been widely validated and used in clinical practice and 
research for over 60 years, there is a paucity of evidence on its utility in patients 
undergoing liver transplantation. We examined the extent to which pre-transplant 
functional status is associated with increased risk of mortality and/or graft failure at 1-
year post-transplant. 
Methods: This retrospective cohort study included 38,278 U.S. adults (≥ 18 years) who 
underwent first, non-urgent, liver-only transplantation from 2005 to 2014 (Scientific 
Registry of Transplant Recipients). We used the KPS to categorize patients as having 
functional impairment/disability that is Severe (10–40%), Moderate (50–70%), or 
None/Normal (80–100%) and examined the risk of patient and graft survival using 
multivariable-adjusted Cox survival regression models. 
Results: The median age of this population was 56 years, 31% were women, and median 
laboratory-calculated pre-transplant MELD was 18. Functional impairment/disability was 
present in 70%; approximately one-quarter was severely impaired. After controlling for 
key recipient and donor factors, severely and moderately impaired/disabled patients had a 
1-year mortality rate that was 1.73 (95% confidence interval (CI): 1.56–1.91) and 1.32 
(CI: 1.21–1.44) times higher than patients with normal functional status, respectively. 
Subjects with severe and moderate disability also had multivariable-adjusted 1-year graft 
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failure rates that were 1.16 (CI: 1.02–1.31) and 1.13 (CI: 1.02–1.24) times higher than 
patients with normal function, respectively. 
Conclusions: Pre-transplant functional status is an important prognostic indicator for 1-
year post-transplant patient and graft survival for liver transplant recipients. 
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INTRODUCTION 
 Due to increasing organ shortages in the U.S., patients on the liver transplant 
waiting list are older and sicker than ever before and wait time continues to climb 
(10,197). Among the 15,000 patients with End-Stage Liver Disease on the transplant 
waiting list in 2013, 20% were over 65 years old, 20% had been waiting for at least 5 
years already, 20% died while awaiting transplant, and fewer than 6,000 patients received 
an organ in 2013 (10). In 2002, in response to increasing shortages and waitlist mortality, 
the liver allocation system was reorganized to prioritize patients according to urgency 
(196). “Urgency” was defined according to risk of 3-month mortality, calculated using 3 
objective laboratory parameters (creatinine, bilirubin, international normalized ratio) to 
create individualized Model for End-Stage for Liver Disease (MELD) scores used to rank 
patients. Although this system successfully lowered population-level waitlist mortality 
rates, it is an insufficient summary measure for describing global health status 
(19,25,26,198), and has recently been shown to underestimate mortality risk among 
subgroups of “frail” patients (25,30,31). 
Frailty syndrome is defined by a cluster of subtle signs and symptoms that were 
originally observed in a geriatric population, but also hallmark sequelae of liver disease: 
malnutrition, sarcopenia, functional impairment/disability, and ultimately, increased 
vulnerability to stressors due to depleted physiologic reserve (86). Frailty is increasingly 
recognized as an important predictor of outcomes after many different major surgical 
procedures, including liver transplantation (34–39,50,199,200,227,228). However, there 
is no gold standard measure of frailty (229). At present, U.S. liver and lung transplant 
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centers are mandated to submit Karnofsky Performance Status (KPS) functional status 
data on all patients, with other clinical data, to the Organ Procurement and 
Transplantation Network (OPTN) each quarter. The KPS scale has been widely validated 
across many disease groups, including End-Stage Renal Disease, and has been widely 
used in clinical practice and research for over 60 years (51,64,66,67,101,114,131,201–
218). Several studies have used KPS as a predictor of liver transplant outcomes, but the 
studies were limited in generalizability as they were single-center studies (32,201), 
outside of the U.S. (199,200), limited to the early post-transplant period (199,200), and/or 
took place before MELD implementation at which point the transplant recipient 
population shifted dramatically (201,230). In 2013, the Liver and Intestinal Transplant 
Committee of OPTN publically asked for researchers to fill the gap in the literature on 
the utility of the KPS scale in a national liver transplant population (218). 
 To our knowledge, this will be the first study to evaluate a standardized, validated 
measure of functional status as a predictor of transplant survival in a national U.S. liver 
transplant population. Using data from the only comprehensive nationwide transplant 
database, the United Network for Organ Sharing (UNOS) Scientific Registry of 
Transplant Recipients, we assessed the clinical utility of the Karnofsky Performance 
Status (KPS) scale for the prediction of 1-year post-liver transplant patient and graft 
survival. 
 
METHODS 
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Study Design and Sample 
 This retrospective cohort study used data from the Scientific Registry of 
Transplant Recipients (SRTR). The SRTR is contracted to UNOS by the U.S. 
Department of Health and Human Services to manage data collected via government-
mandated reporting by all U.S. transplant centers (195). 
 The study population included patients that underwent a first liver transplant 
between January 1, 2005 and October 1, 2014 (Figure 1). Exclusion criteria consisted of 
the following: 1) pediatric transplant (< 18 years), 2) multi-organ transplant, 3) UNOS 
Status 1 or acute liver failure (231,232), 4) Intensive Care Unit (ICU) pre-transplant, or 
4) subjects with missing data in any of the key variables of interest (variables with ≥ 5% 
missing values were not used in this study). We excluded urgent (Status 1 or acute 
hepatic necrosis) and ICU-admitted patients. This was done because these are often 
patients who rapidly decline due to an inciting event (e.g., infection) and may, therefore, 
be categorized as being of poor functional status due to the event as opposed to being 
truly "frail," which is conceptualized as a chronic process leading to depletion of 
physiologic reserve. 
  
Data Collection 
Exposure Variable 
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 The primary exposure of interest was provider assessment of preoperative ("pre-
transplant") functional status using the Karnofsky Performance Status (KPS) scale (Table 
1.1). The KPS defines functional status on an 11-point scale from 100% (normal, no 
complaints, no evidence of disease) to 0% (dead) in 10% increments, with 3 
corresponding tiers. We used the 3-tiered version of the scale based on higher inter-rater 
reliability scores (201,202,210). We assigned labels to the categories with respect to level 
of functional impairment/disability as follows: subjects with minimal or no symptoms of 
disease (80–100%) were labeled "(A) None/Normal [function]"; subjects needing varying 
levels of assistance in daily activities (50–70%) were labeled "(B) Moderate [impairment 
in function]"; and subjects who were disabled and/or hospitalization indicated and/or 
moribund (10–40%) were labeled "(C) Severe [functional impairment/disability]."  
 
Study End Points 
 The primary outcome of interest was 1-year all-cause mortality (Social Security 
Death Master File/Organ Procurement and Transplant Network). We also examined death 
rates during the 1-month postoperative period (day 0–30) as compared to residual risk 
during the remaining 11 months of the year (day 31–365). Since mortality after 
transplantation is highest in the early postoperative period and likely related to operative 
risks and complications that may become less relevant for long-term outcomes, the 
importance of functional status may change with time and context (233). The secondary 
outcome of interest was 1-year graft failure.  
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 Lastly, among patients who did not experience either adverse outcome (death or 
graft failure), we describe the proportion that was able to return to "Normal" functional 
status during the first year post-transplant. Transplant centers must report follow-up data 
on transplant recipients at 6-months post-transplant, 1-year, and annually thereafter; 
follow-up records from day 0 to 395 (365+30 days) with functional status data available 
(< 5% of recipients were missing follow-up functional status) were analyzed (but counted 
once per patient). 
 
Potential Confounding Variables 
 Potential confounders were identified from a priori clinical knowledge, literature 
review, and variables included in the SRTR risk-adjustment models, available at srtr.org 
(234). Potential confounders included recipient sociodemographic and medical/surgical 
history factors (i.e. information known at least 2 weeks before transplant, e.g. primary 
liver diagnosis; Table 4.1), pre-transplant illness severity markers (e.g. last-calculated 
laboratory MELD (233); Table 4.2), and all Donor Risk Index (235) factors (e.g. cause of 
death; Table 4.3) as potential confounding variables. Every variable evaluated for 
potential confounding was categorized and described in Tables 4.1–4.3 (exceptions: 
baseline functional status, time on the waitlist, and MELD component labs are listed for 
descriptive purposes only). 
 
Statistical Analysis 
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 We explored bivariate relationships between the primary exposure (functional 
status) and potential confounders of interest using contingency table analyses (chi-
squared (χ2) tests for categorical variables, ANOVA for continuous variables, and 
Spearman's rho (rs) for ordered-variable correlations, using expanded KPS, continuous 
MELD). Relationships between variables and post-transplant time were explored 
graphically. One-year cumulative failure rates were estimated using the Kaplan Meier 
method. 
 To quantify the extent to which impaired functional status was associated with 
increased risk of 1-year all-cause mortality and 1-year graft failure, we developed 
separate Cox survival regression models for each outcome. We applied a manual forward 
approach, sequentially adding conceptually meaningful groups of variables to the model. 
With the exception of recipient age, sex, race/ethnicity, and MELD, variables (and 
variable interactions) with p-values of > 0.05 were excluded from the final model. 
Goodness-of-fit and proportionality of hazards were tested using the omnibus Gronnesby 
and Borgan test and martingale residuals and confirmed non-significant (no evidence of 
poor fit) for all models reported (236). 
Results are reported as hazard ratios (HR) and accompanying 95% confidence 
intervals (CI); p-values ≤ 0.05 were considered statistically significant. All analyses were 
conducted using Stata version 13 (StataCorp LP, College Station, TX). This study was 
deemed exempt by the University of Massachusetts Medical School Institutional Review 
Board. 
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RESULTS 
 
Sample Characteristics  
The final study sample included 38,278 liver transplant recipients (Figure 4.1). 
The median (interquartile range [IQR]) age was 56 (51–61) years and MELD was 18 
(12–25). Women represented 31% of the sample and the largest ethnic minority was 
Hispanic/Latino (12.7%). Median follow-up time was 3.3 (1.5–6.0) years after transplant. 
At pre-transplant assessment, approximately 70% of the sample had some degree 
of functional impairment or disability. Approximately one-quarter (23.7%) had “Severe” 
functional impairment/disability (≤ 40% function), 45.8% were “Moderately” impaired, 
and the remaining 30.5% had no functional impairments (≥ 80% function). The median 
(IQR) pre-transplant functional performance status score was 60% (50–80%) and the 
mean (standard deviation) was 61% (21%). 
 
Baseline Characteristics and Changes over Waitlist Course 
Table 4.1 describes baseline characteristics of the sample by category of pre-
transplant functional status. Subjects who were of worse functional status pre-transplant 
were more likely to be female, of Hispanic/Latino race/ethnicity, and/or have Medicaid 
insurance. Primary diagnosis of hepatic malignancy was associated with better physical 
function. Baseline and pre-transplant functional status were moderately correlated (rs = 
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0.42, p < 0.001). Sixty-percent of recipients maintained the same level of function over 
their waitlist course while 30% declined from a higher level of function at baseline. 
Table 4.2 describes recipient clinical characteristics pre-transplant by category of 
pre-transplant functional status. Significant weight loss (≥ 5% of baseline weight) over 
the waitlist period was more common among transplant recipients who were 
impaired/disabled pre-transplant, and the weight loss occurred more rapidly; more 
disabled patients had shorter average wait times compared to patients of Normal 
functional status. Poor functional status was moderately correlated with worse (higher) 
MELD scores (rs = -0.49; p < 0.001). However, only 64% of subjects with MELD scores 
≥ 30 were “Severely” impaired/disabled, and less than half (44%) of patients with MELD 
scores < 15 were of “Normal” functional status. Cirrhosis severity according to Child-
Pugh class was associated with severity of functional status. However, twice as many 
subjects were classified as Child C (severe) than were considered to have severe 
functional impairment/disability (20,937 versus 9,074). Around 10% of severely impaired 
subjects were on dialysis pre-transplant, compared to < 1% of Normal functional status 
subjects. 
 Table 4.3 describes donor characteristics by categories of pre-transplant 
functional status. Donor characteristics were mostly comparable across functional status 
categories. Only 8.3% of living donor liver transplant recipients was Severely 
impaired/disabled (n = 729). Functionally impaired patients were slightly less likely to 
receive higher risk organs (e.g. donor ≥ 70 years, nationally allocated or with prolonged 
cold ischemia time). 
75 
 
 
All-Cause Mortality 
Death within one year was observed in 3,595 (9.4%) transplant recipients. The 
mortality rate was directly related to functional status. Among patients that were severely 
impaired/disabled, 12.8% died compared with 9.3% of those with moderate functional 
limitations and 6.9% of those with normal functional status at the time of transplant. 
Table 4.4 describes the results of unadjusted and adjusted Cox regression models 
for 1-year mortality. Subjects with severe or moderate functional impairment pre-
transplant were at significantly increased risk of dying within one year post-transplant. 
After multivariable adjustment, severely and moderately impaired patients had 1-year 
mortality rates that were 1.73 (CI: 1.56–1.91) and 1.32 (CI: 1.21–1.44) times greater than 
the hazard for subjects without any functional impairment, respectively. 
Mortality risks were greatest in the immediate postoperative period (day 0–30) 
when 881 (2.3%) deaths were observed in a single month. The adjusted 30-day mortality 
risk for Severely impaired/disabled patients was more than double (HR: 2.10; CI: 1.71–
2.59) that of patients of “Normal” functional status, after adjusting for all variables 
controlled for in the full 1-year survival model (Table 4.4). Approximately three-quarters 
(n = 2,714) of all one-year deaths occurred during the remaining 11 months of the 
postoperative year (day 31–365); HRs were comparable to estimates for overall one-year 
mortality (< 10% relative difference). 
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Graft Failure 
 Graft failure was observed in 2,214 of the study population within one year of 
transplant. The estimated failure rate on day 365 was 6.2% (cumulative failure or death 
rate on day 365: 12.7%). Approximately half (53.8%) received a second transplant within 
the first post-transplant year, of which 75.9% (n = 905) survived the year; 98.6% (n = 
1,008) of those who did not undergo retransplantation within the first postoperative year 
did not survive to 1-year post-transplant.  
Table 4.5 describes the results of unadjusted and adjusted Cox regression models 
for 1-year graft failure. Subjects with severe and moderate impairment/disability had 
multivariable-adjusted 1-year graft failure rates that were 1.16 (CI: 1.02–1.31) and 1.13 
(CI: 1.02–1.24) times higher than patients with normal function, respectively. 
 
Functional Status Post-Liver Transplant 
 Among the 33,764 (88.2%) transplant recipients who experienced neither 
outcome (death or graft failure within a year), 95% (n = 32,004) had at least 1 follow-up 
functional status assessment within a year. The majority (86.3%) recovered from 
transplant and reached "Normal" functional status within 1 year. Of the 7,258 recipients 
in this subsample that were severely impaired/disabled pre-transplant, 81% (n = 5,861) 
recovered full physical function ("Normal" functional status) within 1 year of transplant. 
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DISCUSSION  
 Almost 1 in 4 patients included in this national study of 38,278 U.S. adults that 
underwent non-urgent liver transplantation between 2005 and 2014 had severe functional 
impairment/disability at the time of transplant. This group of patients was found to have a 
markedly increased hazard of dying and/or having graft failure at 1 year compared to 
Normal functional status patients. This increased hazard was observed in both unadjusted 
and multivariable-adjusted regression analyses controlling for a variety of potentially 
confounding factors of prognostic importance. Approximately 86% of recipients who did 
not experience 1-year death or graft failure (and had follow-up data available) recovered 
from transplant and reached "Normal" functional status within 1-year. 
 We present data from the first national study illustrating the role of pre-transplant 
functional status as a predictor of one-year survival among liver transplant recipients. Our 
results are in agreement with the findings from earlier studies that evaluated Poor 
functional status as a predictor of adverse transplant outcomes (32,199–201). Two such 
studies, each with approximately 4,000 U.K. recipients of a liver transplant, reported a 
near 2-fold increased risk of post-transplant mortality at 90 days for the worst functioning 
group relative to the highest functioning group (199,200). Studies have also shown that 
objective measures of physical function, such as walking distance or speed and grip 
strength, are also strong predictors of adverse liver transplant outcomes regardless of 
recipient age, size, or cause/severity of liver disease (32). 
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Implications 
  Insight into a transplant patient’s global health status guides day-to-day clinical 
management, as well as transplant decisions, particularly in the face of contradictory 
laboratory or otherwise objective measures of pathological disease progression (e.g. 
MELD score). Capturing such insight through the use of a quantitative physical health 
scale may help transplant teams to strategize and communicate complex medical and 
surgical management decisions with patients, families, and the many other members of 
multidisciplinary transplant teams that provide longitudinal care for liver transplant 
patients. 
 Knowledge of a patient’s functional status before transplant may practically assist 
transplant teams to anticipate, communicate, and coordinate resources for postoperative 
critical care, rehabilitation after discharge, and potentially longer-term occupational 
therapy to help patients recover physical health and quality of life (237). Many well-
established risk factors for adverse outcomes among patients undergoing liver transplant 
may be unpredictable or sudden (spontaneous bacterial peritonitis), unavoidable (older 
age), and/or untreatable (portal vein thrombosis). Furthermore, many of the strongest 
predictors of adverse outcomes are present in a relatively small percentage of the liver 
transplant population. Many risk factors are unknown until very close to transplant time 
(e.g. life support, cold ischemia time), whereas functional impairment can present very 
early and progress insidiously in end-stage liver disease patients over the course of 
waiting for an organ. All patients can also be assigned a value for functional status at 
baseline, which can be used as a reference point to assess change over time. While this 
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scale is an all-encompassing global physical function measure and a patient can fall 
anywhere on the continuous scale, many risk factors considered in transplant decisions 
are individual dichotomous variables, which are usually assessed in combination with 
other risk factors that can take time to accumulate. Thus, as functional status is a 
harbinger of adverse outcomes and may present early, it may be a useful clinical tracking 
tool that can be used for strategic care management. 
  Promising interventional studies have also shown that “prehabilitation,” physical 
therapy (e.g. strength training) and nutritional support, designed to improve functional 
status (or slow decline) in anticipation of a physiologic stressor such as surgery 
(137,138), is effective at improving postoperative recovery and outcomes after major 
abdominal surgery (54,55,60–62). Although none of these studies focused on liver 
transplant patients, several included cohorts that similarly have a high likelihood of 
becoming frail due malnutrition, inflammation, and sarcopenia (e.g. cancer patients 
(55,61) and older populations (60,62)). Prehabilitation has the potential for providing 
clinicians with a way to not only recognize, but also slow or prevent decline to the point 
of “Severe” impairment/disability. However, more research on prehabilitation specific to 
a liver disease population is warranted. Frailty due to liver failure may not respond to the 
same interventions that have successfully slowed progression of frailty due to aging as 
there may be fundamental differences in etiology and pathogenesis between these 
populations that may limit their effectiveness (226). 
  
Strengths and Limitations 
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Strengths of this study include its use of the SRTR with complete capture of every 
solid organ transplant in the U.S. since 1987, including waitlist, donor, follow-up, and 
external data file linkages (e.g. Social Security Death Master File). Mandated reporting of 
KPS providing more than a decade of nationally representative data on functional status 
is also a major strength of our investigation. 
 This study relies on the Karnofsky Performance Status scale as the only available 
measure of functional status in the SRTR. Limitations to using KPS to represent 
functional status on a national scale include: 1) lack of adequate validation in the liver 
transplant population, 2) subjectivity of the scale (relative to direct measures of frailty 
such as grip strength) which may result in heterogeneity across transplant centers 
depending on how, when, and by whom the variable is measured, and 3) vulnerability to 
transplant center "gaming" due to its inclusion as a risk-adjustment factor for SRTR-
generated outcomes reports serving as the basis for federal regulatory action when 
outcomes are below-expected (218). 
 The KPS has been included in validation studies in transplant populations, where 
it has been compared with the Short Form survey and other physical function scales in 
liver, as an outcome (207), and has also been extensively validated in end-stage renal 
disease as a predictor (101,114). Results of validation studies across disease groups have 
shown excellent interrater reliability when the Karnofsky is used as a 3-tiered scale, 
regardless of provider type (201,202,210). Furthermore, an online SRTR analysis of 
measure variability across transplant centers and relationship with regulatory decisions on 
flagging centers found that inter-center variation had an impact on only a few centers' 
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outcomes enough to affect CMS auditing decisions. Lastly, we expect suspected 
"gaming" could result in some centers exaggerating their patients' functional status 
scores; this would mean that the risk estimates we report in this study have been 
artificially diluted by such behavior, and that "truly" impaired patients have even higher 
hazard ratios than we were able to show. 
Finally, this study was limited to evaluating the KPS scale though there may be 
other, more appropriate scales to use in this population. Several different measures of 
physical function and composite frailty scores have been used in the literature and were 
effective predictors of waitlist and transplant outcomes. However, direct measures of 
frailty would demand more resources (time, training, materials) from transplant centers 
than the KPS alone, and should be compared with KPS for predictive value (area under 
the curve) before changing current practices. Future research may show that a liver 
transplant-specific functional status scale, incorporating additional objective parameters, 
may better suit this population's needs. 
 A better understanding of this phenomenon could help transplant centers to 
dynamically monitor patients on ever-growing waiting lists from a more comprehensive 
standpoint than MELD rank alone. 
 
CONCLUSIONS 
 In summary, we have demonstrated the importance of a simple 3-point functional 
status scale for predicting one-year liver transplant outcomes. We highlight areas where 
future research may further the validity, and ultimately, the clinical utility of the 
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Karnofsky Functional Performance scale in a liver transplant population. It is important 
to continue to develop objective measures for describing global health status and illness 
severity to help in the allocation of organs and waitlist management, patient health 
improvement, and accurate adjustment for transplant center case-mix for transplant 
reimbursement. 
83 
 
Table 4.1: Baseline characteristics† by pre-transplant functional status, Scientific 
Registry of Transplant Recipients 2005–2014 (n = 38,278) 
  Functional impairment/disability 
  
A 
None 
B 
Moderate 
C 
Severe 
Characteristic* (n = 11,674) (n = 17,530) (n = 9,074) 
    
Sociodemographics    
Age in years       
18–44 11.6 10.3 12.7 
45–54 28.9 30.2 32.1 
55–64 44.9 45.3 43.2 
≥ 65 14.5 14.3 12.0 
Women 26.8 32.1 33.4 
Race/ethnicity       
White 73.1 74.3 70.4 
Hispanic/Latino 10.6 12.5 15.9 
Black 8.9 8.4 9.1 
Health Insurance       
Private 68.1 55.3 54.2 
Medicare 18.5 26.5 24.6 
Medicaid 8.8 14.0 17.0 
Medical/Surgical History       
Functional impairment at registration       
None  74.6 33.4 22.4 
Moderate 19.9 57.0 35.4 
Severe 2.5 6.6 37.0 
Primary cause of liver disease       
Non-Cholestatic 56.2 64.7 75.8 
Cholestatic 9.5 8.1 7.8 
Malignancy 30.1 23.0 12.5 
Hepatitis C 44.4 45.5 42.1 
Diabetesa 23.2 25.8 25.3 
Previous Abdominal Surgery 46.2 51.6 50.3 
    
All distributions varied significantly across categories of functional status (p<0.001) 
†Characteristics known at least 2 weeks prior to transplant 
*Column percentage 
aDiabetes types 1, 2, or unspecified 
 
n: number in group; p: probability 
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Table 4.2: Pre-transplant clinical characteristics by pre-transplant functional status, 
Scientific Registry of Transplant Recipients 2005–2014 (n = 38,278) 
  Functional impairment/disability 
  
A 
None 
B 
Moderate 
C 
Severe 
Characteristic* (n = 11,674) (n = 17,530) (n = 9,074) 
Waitlist time, months 4.0 (1.3–10.2) 3.7 (1.1–10.3) 2.1 (0.4–8.4) 
Weight loss ≥ 5%a 19.7 24.2 27.0 
BMI, kg/m2       
Underweight (<18.5) 1.6 1.6 2.4 
Normal (18.5–< 25) 28.3 27.5 27.1 
Overweight (25–< 30) 37.0 36.0 34.0 
Obese (≥ 30) 33.2 35.0 36.5 
MELD       
< 15 49.9 34.9 14.3 
15–29 45.9 56.5 45.9 
≥ 30 4.2 8.6 39.8 
Total bilirubin 2.3 (1.2–4.4) 3.0 (1.6–6.1) 6.6 (2.9–17.2) 
International normalized ratio 1.4 (1.2–1.7) 1.5 (1.3–1.9) 2.0 (1.5–2.6) 
Serum creatinine 0.9 (0.7–1.2) 1.0 (0.8–1.3) 1.4 (0.9–2.3) 
Serum sodium 137 (134–140) 136 (133–139) 135 (132–139) 
Child Pugh score       
A (Good) 23.8 11.8 4.1 
B (Fair) 38.7 33.8 18.5 
C (Poor) 37.5 54.4 77.4 
Ascitesb       
None 36.9 23.0 14.0 
Mild/Moderate 48.4 52.4 43.5 
Severe 14.8 24.6 42.6 
Encephalopathyc       
None 52.7 36.6 26.0 
Grade 1–2 44.4 57.5 61.4 
Grade 3–4 2.9 5.9 12.6 
Albumin       
> 3.5 26.7 19.3 22.8 
2.8–3.5 41.7 41.2 39.0 
< 2.8 31.6 39.6 38.2 
Dialysisd 0.9 1.6 10.9 
Portal Vein Thrombosis 6.5 9.7 12.4 
All distributions varied significantly across categories of functional status (p < 0.001) 
*Column percentage or median (interquartile range) 
aRelative to weight at time of waitlist registration 
bMild/Moderate ascites: diuretic-responsive; Severe ascites: diuretic-refractory 
cEncephalopathy grade 1–2 (or precipitant-induced); Grade 3–4 (or chronic) 
dDialyzed at least twice in prior week 
 
BMI: body mass index; kg: kilograms; m: meters; MELD: Model for End-Stage Liver 
Disease; n: number in group; p: probability 
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Table 4.3: Donor characteristics by pre-transplant functional status, Scientific Registry of 
Transplant Recipients 2005–2014 (n = 38,278) 
  Functional impairment/disability   
  
A 
None 
B 
Moderate 
C 
Severe 
  
Characteristic* (n = 11,674) (n = 17,530) (n = 9,074) p-value 
     
Transplant type: Living donor 5.5 5.0 2.3 < 0.001 
Donor Risk Indexa 1.6 (1.3–1.9) 1.6 (1.3–1.9) 1.5 (1.2–1.9) < 0.001 
Age in years         
18–39 37.3 37.1 39.9   
40–49 19.7 19.7 19.7   
50–59 19.8 20.4 20.7   
60–69 11.7 12.7 10.8   
≥ 70 5.5 4.9 3.9 < 0.001 
Women 40.5 41.4 40.9 0.35 
Race/ethnicity        
White 68.2 68.1 65.6   
Black 17.2 17.9 17.5   
Other 14.6 14.0 16.9 < 0.001 
BMI, kg/m2         
Underweight (< 18.5) 2.9 2.9 2.6   
Normal (18.5–< 25) 36.5 35.9 36.2   
Overweight (25–< 30) 33.5 34.2 33.4   
Obese (≥ 30) 27.1 27.0 27.9 0.43 
Cause of death         
Trauma 34.3 34.1 34.1   
Anoxia 21.5 22.5 24   
Cardiovascular accident 41.4 40.9 39.4 < 0.01 
Donation after cardiac death 12.6 13.2 12.1 0.04 
Split/Partial liver 1.5 1.4 1.3 0.38 
Allocation type         
Regional 17.8 19.9 23.3   
National 6.6 5.0 3.8 < 0.001 
Cold ischemia time ≥ 8 hours 30.9 28.9 27.9 < 0.001 
     
*Column percentage or median (interquartile range) 
aDonor risk index as described by Feng et al 2006 
 
BMI: body mass index; kg: kilograms; m: meters; n: number in group; p: probability 
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Table 4.4: Association between pre-transplant functional status and 1-year (all-cause) 
post-transplant mortality, Scientific Registry of Transplant Recipients 2005–2014 (n = 
38,278†) 
Functional impairment 
/disability 
 
Hazard Ratio (95% CI) 
  
 1-Year 
 Unadjusted  Adjusteda 
    
Severe 1.94 (1.77–2.13)  1.73 (1.56–1.91) 
Moderate 1.38 (1.27–1.51)  1.32 (1.21–1.44) 
None Referent  Referent 
    
 Day 0–30b  Day 31–365c 
 Unadjusted Adjusteda  Unadjusted Adjusteda 
      
Severe 2.40 (1.99–2.89) 2.10 (1.71–2.59)  1.82 (1.64–2.02) 1.62 (1.45–1.82) 
Moderate 1.60 (1.34–1.92) 1.53 (1.27–1.83)  1.33 (1.20–1.46) 1.26 (1.15–1.40) 
None 
Referent  Referent 
 
   
†Adjusted model n = 38,0762 (missing albumin (n = 1) or donor body mass index (n = 
200)) 
aAdjusted for recipient age, sex, race, insurance, BMI, diabetes, previous abdominal 
surgery, liver disease, MELD, albumin, portal vein thrombosis, dialysis; donor age, race, 
BMI, donor type (living or deceased) and cause of death, donation after cardiac death, 
allocation type, cold ischemia time ≥ 8 hours; interactions: recipient BMI and diabetes, 
recipient hepatitis C and portal vein thrombosis, recipient hepatitis C and donor age. 
bPostoperative day 0–30: n = 38,278; 881 deaths 
cPostoperative day 31–365: n = 37,352; 2,714 deaths 
 
BMI: body mass index; CI: confidence interval; MELD: Model for End-Stage Liver 
Disease; n: number in group 
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Table 4.5: Association between pre-transplant functional status and 1-year graft failure, 
Scientific Registry of Transplant Recipients 2005–2014 (n = 38,278) 
  
Hazard Ratio (95% CI) 
Functional impairment 
/disability Events, n* Unadjusted Adjusteda 
    
Severe 527 1.10 (0.98–1.23) 1.16 (1.02–1.31) 
Moderate 1,051 1.12 (1.01–1.23) 1.13 (1.02–1.24) 
None 636 Referent Referent 
    
*Number of graft failures within 1 year of liver transplantation 
aAdjusted for recipient age, sex, race, BMI, primary diagnosis of liver disease, MELD, 
portal vein thrombosis; donor age, race, BMI, donor type (living or deceased) and cause 
of death, donation after cardiac death, cold ischemia time ≥ 8 hours; interactions: 
recipient hepatitis C and portal vein thrombosis, recipient hepatitis C and donor age. 
 
 
BMI: body mass index; CI: confidence interval; MELD: Model for End-Stage Liver 
Disease; n: number in group 
88 
 
Figure 4.1: Study inclusion/exclusion criteria flow chart. Scientific Registry of 
Transplant Recipients 
 
 
 
 
aRe-transplants were not included in analyses 
bPercent = N remaining / N starting sample
 
cOnly variables with < 5% missing values were considered  
dDeceased donor cold ischemia time (living donor values corrected to median) 
 
 
N: number in study population; n: number in group 
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CHAPTER V 
FINAL SUMMARY & CONCLUSIONS 
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In this dissertation, we 1) evaluated the impact of transplant policy on incidence 
of candidate delisting due to “too sick to transplant” (Chapter II); 2) described the 
relationship between objective (sarcopenia) and subjective (functional status, KPS) 
measures of pre-transplant frailty (Chapter III); and 3) quantified the extent to which 
patients that are of poor functional status pre-transplant are at increased risk of 1-year 
post-transplant mortality and graft failure (Chapter IV). 
 
CMS Policy and Trends in “Too Sick to Transplant” Delisting 
In Chapter II, we examined national epidemiologic trends in incidence of waitlist 
removal on account of the patient being too frail to benefit from transplant (“too sick to 
transplant”), using more than a decade of national data (Scientific Registry of Transplant 
Recipients (SRTR)) from 2002 to 2012. Given the adverse effects that CMS Conditions 
of Participation policy has been shown to have on risk aversion among centers “flagged” 
for poor performance, we hypothesized that there would be a significant impact of COP 
implementation on trends in candidate removal from the liver transplant waitlist due to 
"illness severity" at the national level. 
We observed increasing trends in delisting due to "illness severity" in the setting 
of comparable demographic and clinical characteristics. Delisting abruptly increased at 
the time of COP implementation and likelihood of being delisted continued to increase 
without attenuation over the duration of the study period. In contrast, COP 
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implementation had no significant impact on 1-year post-transplant mortality trends or 
incidence. 
The implications of these findings are that patients who could potentially benefit 
from transplant are increasingly being denied this life-saving procedure while transplant 
mortality rates remain unaffected. The National Organ Transplant Act, the Institute of 
Medicine, and the Final Rule consistently supported 3 goals: to increase transplantation, 
to decrease waitlist mortality, and to maximize transplant benefit. However, we conclude 
that although the COP policy was a CMS quality initiative designed to improve patient 
outcomes, in reality, it failed to show beneficial effects for the liver transplant population 
overall. 
Future studies on understanding these trends and efforts to rebalance the waitlist-
transplant outcome scale are warranted, and this balance should be considered during 
future development of national policies and in clinical decision-making in order to better 
serve this patient population. 
 
Association between Functional Status and Sarcopenia 
In Chapter III, we explored the relationship between objective and subjective 
parameters of liver transplant patient frailty. We measured decline in lean core muscle 
mass (“sarcopenia”) on abdominal CT scans collected retrospectively at a single U.S. 
transplant center between 2006 and 2015. The relationship between objective sarcopenia 
measures and subjective functional status, as assessed by transplant providers using the 
Karnofsky Functional Performance scale, was described and quantified. 
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The majority of the sample exhibited signs (70% with muscle wasting) and/or 
symptoms (86% with functional impairment) of frailty syndrome. Measures of sarcopenia 
including rate of muscle wasting and size of LPA pre-transplant were associated with 
elevated risks of functional impairment, disability, and/or being moribund pre-transplant. 
Our findings were in agreement with a recent study that asked a similar question in a 
different study population of aged (> 70 years) patients admitted for general surgery 
procedures at University of Michigan.  
We concluded that the overall correlation between provider-assessed physical 
health status and sarcopenia in our sample was moderate. More research on the 
relationship between these variables is warranted. Understanding the clinical utility of 
using either or both measures for prognostication and management of high-risk liver 
transplant patients would further understanding of frailty and advance the field in refining 
and improving upon existing tools for assessing and describing illness severity in this 
population. 
 
Association between Functional Status and Outcomes after Liver Transplantation 
In Chapter IV, we quantify the extent to which pre-transplant functional 
impairment/disability (KPS) is associated with worse patient and/or graft survival within 
1-year post-liver transplant using a decade of national data from 2005 to 2014 (SRTR). 
The majority of the sample (70%) was functionally impaired pre-transplant. Severely 
impaired patients had markedly increased hazards for both death and graft failure within 
1-year of transplant compared to Normal functional status patients. These increased risks 
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were observed in both unadjusted and multivariable-adjusted survival regression analyses 
controlling for a variety of potentially confounding factors of prognostic importance. 
Among subjects who experienced neither outcome and had follow-up data on 
postoperative functional status available, the majority (86%) recovered from transplant 
and reached "Normal" functional status within the first post-transplant year. We conclude 
that pre-transplant functional status is an important prognostic indicator of 1-year post-
transplant outcomes. 
It is important to continue to develop objective measures for describing global 
health status and illness severity to help in the allocation of organs, waitlist management, 
patient health improvement, and accurate adjustment for transplant center case-mix for 
transplant reimbursement. 
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SUPPLEMENTAL TABLES FOR CHAPTER III 
Supplemental Table 3.1: Characteristics of the overall study cohort of UMass liver 
transplant recipients by inclusion/exclusion status, 2006‒2015 (n = 402) 
Characteristic* 
Included 
(n = 136) 
Excluded 
(n = 266) p-value 
Age in years 55.4 ± 9.5 55.6 ± 9.5 0.81 
Women 33.8 (46) 39.1 (104) 0.30 
Ethnicity    
White 77.2 (105) 84.4 (221)  
Hispanic/Latino 14.7 (20) 11.8 (31)  
Primary insurance    
Private 39.0 (53) 41.4 (110)  
Public-Medicaida 34.6 (47) 28.2 (75)  
Public-Medicare 26.5 (36)  27.4 (73) 0.14 
Body Mass Index, kg/m2 28.2 ± 5.6 28.8 ± 6.8 0.60 
Weight, kg 81.9 ± 19.6 83.1 ± 21.5  0.60 
Height, m 1.70 ± 0.1 1.70 ± 0.1 0.69 
Diabetesb 24.3 (33) 27.8 (74) 0.45 
Primary Cause of Liver Disease     
Hepatitis C and similar infections 47.1 (64) 34.2 (91)  
Alcoholic Hepatitis 24.3 (33) 38.4 (102)  
Other liver diseases 28.7 (39) 25.9 (69) < 0.01 
Hepatocellular Carcinoma 36.0 (49) 16.9 (45) < 0.001 
MELD score, pre-transplant  22.3 ± 10.5 18.7 ± 11.0 < 0.01 
Creatinine 1.8 ± 1.6 1.5 ± 1.1 0.02 
Total bilirubin 9.0 ± 11.1 8.3 ± 11.6 0.62 
International Normalized Ratio 2.0 ± 1.7 1.7 ± 0.8 < 0.01 
Albumin 3.0 ± 0.8 2.9 ± 0.8 0.37 
Child-Pugh class, pre-transplant    
A (mild) 7.4 (10) 6.0 (16)  
B (moderate) 24.3 (33) 30.5 (81)  
C (severe) 68.4 (93) 61.7 (164) 0.20 
Waitlist time, months 3.2 (0.8–12.4) 3.4 (0.9–10.1) 0.96 
Portal Vein Thrombosis 15.4 (21) 13.9 (37) 0.12 
Medical condition    
Home 52.2 (71) 63.2 (168)  
Hospital 26.5 (36) 18.8 (50)  
ICU 21.3 (29) 15.0 (40) 0.02 
Life Support 11.8 (16) 10.2 (27) 0.12 
Functional Statusc 47.3 ± 24.8 49.3 ± 23.2 0.42 
Muscle wasting  
n/a Lean psoas area 71.3 (97) 
Size, total psoas area 72.8 (99) 
Quality, mean density 55.2 (75) 
*% (n), mean ± standard deviation, or median (interquartile range) 
aIncludes 1 person with “public insurance-other”  
bDiabetes type 1, 2, or unspecified 
c Provider-assessed using the Karnofsky Performance Status scale pre-transplant 
CT: Computed Tomography; kg: kilograms; m: meters; MELD: Model for End-Stage 
Liver Disease; n: number; n/a: not applicable 
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Supplemental Table 3.2: Frailty measures: Sarcopenia and functional status by gender, 
UMass liver transplant recipients 2006–2015 (n = 136) 
Psoas Measures* 
Men 
(n = 90) 
Women 
(n = 46) p-valued 
All 
(n = 136) 
BASELINEa        
Time between CTs, 
months 11.6 (4.7–41.4) 13.0 (1.4–33.7) 0.30 12.0 (3.6–36.5) 
TPA 2,344.3 (551.0 1,518.0 (437.8) < 0.001 2,064.8 (646.5) 
Densityb 42.7 (8.8) 41.4 (10.3) 0.45 42.3 (9.3) 
LPA 1,771.1 (474.4) 1,131.1 (349.1) < 0.001 1,554.7 (530.4) 
LPA/hgt2 582.7 (157.1) 435.4 (134.1) < 0.001 532.9 (164.8) 
PRE-TRANSPLANT       
Time from last CT to 
transplant, days 27 (11–47) 26 (11–60) 0.89 27 (11–50.5) 
TPA 2,028.9 (547.7) 1,449.5 (447.7) < 0.001 1,832.9 (583.3) 
Densityb 41.0 (8.3) 37.3 (9.9) 0.023 39.8 (9.0) 
LPA 1,513.2 (451.9) 1,048.6 (354.4) < 0.001 1,356.1 (474.5) 
LPA/hgt2 499.2 (158.2) 403.8 (133.7) < 0.001 466.9 (156.6) 
CHANGE (∆c)      
∆TPA -266.5 (-496.8 to -13.6) -49.6 (-232.4 to 121.4) 0.001 -167.6 (-415.3 to 11.6) 
%∆ TPA -12.6 (16.4) -3.2 (19.0) 0.003 -9.5 (17.8) 
∆Densityb -0.6 (-9.9 to 5.4) -4.2 (-11.4 to 4.0) 0.25 -1.6 (-10.6 to 5.2) 
%∆Densityb -1.5 (-20.2 to 12.0) -10.0 (-24.5 to 16.6) 0.26 -4.5 (-21.1 to 12.3) 
∆LPA -175.7 (-445.2 to -17.7) -26.0 (-272.3 to 67.4) 0.003 -148.2 (-377.4 to 19.1) 
%∆ LPA -13.3 (18.6) -5.7 (21.5) 0.034 -10.7 (19.9) 
∆LPA/hgt2 -51.6 (-145.7 to -6.1) -10.6 (-101.4 to 28.1) 0.008 -48.0 (-130.2 to 6.4) 
RATE OF CHANGE    
∆LPA/hgt2/month -3.2 (-8.8 to -0.6) -0.5 (-7.0 to 2.8) 0.031 -2.65 (-8.5 to 0.2) 
%∆ LPA/month -0.5 (-1.4 to -0.1) -0.1 (-1.6 to 0.8) 0.07 -0.5 (-1.5 to 0.04) 
     
*Mean (standard deviation) or median (interquartile range) 
aBaseline defined as earliest available abdominal CT scan before pre-transplant CT (with 
at least 7 days between scans) 
bMean of left and right psoas muscle densities, Houndsfield units 
c∆= Change from baseline CT to pre-transplant CT, % ∆ = (pre-transplant LPA–baseline 
LPA)/baseline LPA (note: height in the denominator cancels out) 
dWomen versus Men 
 
CT: computed tomography abdominal scan; hgt: height, meters; LPA: lean psoas area 
(TPA x density adjustment factor), mm2; p: probability; TPA: total psoas area (sum of 
left and right psoas muscles as separate measures for pre-transplant and baseline CTs), 
mm2
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Supplemental Table 3.3: Characteristics of liver transplant recipients in relation to 
change in lean psoas area relative to baseline (tertiles), UMass 2006‒2015 (n = 136) 
 
Tertiles of Relative Change in Lean Psoas Area† 
 
Severe  
loss of LPA 
Moderate  
loss of LPA 
Minimal or no  
loss of LPA 
Median ∆LPA (Range): -30.1 (-64.5to -19.0) -9.1 (-18.8 to -1.3) 7.4 (-1.0 to 46.1) 
Months between CTs, median (IQR): 19.7 (8.7–54.9) 9.8 (4.0–31.7) 8.1 (1.8–31.9) 
Characteristic* 
 
  
Age ≥ 55 years 65.2 53.3 55.6 
Women 26.1 26.7 48.9 
Ethnic minority 10.9 33.3 24.4 
Public health insurance  54.4 71.1 57.8 
Body mass index, kg/m2 27.4 (4.8) 29.1 (5.3) 28.1 (6.7) 
Weight, kg 82.6 (18.6) 83.4 (18.2) 79.8 (22.0) 
Height, m 1.7 (0.1) 1.7 (0.1) 1.7 (0.1) 
Diabetesa 30.4 26.7 15.6 
Primary Cause of Liver Disease     
Hepatitis C/viral-other 50.0 46.7 44.4 
Alcoholic Hepatitis 21.7 26.7 24.4 
Other liver diseases 28.3 26.7 31.1 
Hepatocellular Carcinoma 32.6 31.1 44.4 
Time on waiting list, months 2.2 (0.7‒11.1) 4.6 (1.5‒13.0) 3.0 (0.8‒9.1) 
Weight loss per month on waitlist    
< 0‒≤ 5% 41.3 44.4 45.5 
> 5% 21.7 13.3 25.0 
MELD at registrationb 20.5 (11‒26) 15 (10‒22) 15 (10‒20) 
MELD pre-transplantb 25.5 (16‒36) 22 (12‒30) 16 (12‒24) 
Creatinine 1.3 (0.9‒2.5) 1.0 (0.8‒1.6) 1.1 (0.8‒1.8) 
Total bilirubin 6.4 (2.8‒19) 5.0 (1.7‒12.5) 2.9 (1.4‒6.1) 
International Normalized Ratio 1.7 (1.3‒2.2) 1.7 (1.3‒2.3) 1.4 (1.1‒1.8) 
Albumin 3.0 (2.5‒3.4) 2.8 (2.5‒3.5) 3.0 (2.4‒3.3) 
Child Pugh    
B 19.6 22.2 31.1 
C 78.3 66.7 60.0 
Portal Vein Thrombosis 15.2 17.8 13.3 
Medical condition    
Not Hospitalized 41.3 46.7 68.9 
Hospitalized, not ICU 26.1 35.6 17.8 
ICU 32.6 17.8 13.3 
Life support 19.6 8.9 6.7 
    
*%, mean (standard deviation), or median (interquartile range (IQR)) 
†Tertile categories, Severe/Moderate/Minimal: n = 46/45/45 
aDiabetes type 1, 2, or unspecified 
bLaboratory calculated MELD score 
 
IQR: interquartile range; kg: kilograms; m: meters; MELD: Model for End-Stage Liver 
Disease; n: number 
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Supplemental Table 3.4: Characteristics of liver transplant recipients in relation to 
functional status, UMass 2006‒2015 (n = 136) 
 
Functional impairment/disability 
 
Severe 
(n = 62) 
Moderate 
(n = 55) 
None/Normal 
(n = 19) 
Median %Δ LPA (Range): -13.1 (-33.3 to -1.3) -9.5 (-20.9 to 4.0) -2.2 (-8.2 to 0.95) 
Months on the waitlist, median (IQR): 1.7 (0.39–8.7) 4.3 (1.3–13.0) 3.8 (1.2–13.9) 
Months between CT scans, median 
(IQR): 
10.4 (2.7–43.0) 15.0 (4.8–35.4)  16.9 (6.1–35.2) 
Characteristic* 
 
  
    
Age ≥ 55 years 56.5 60.0 57.9 
Women 33.9 33.2 21.1 
Ethnic minority 27.4 18.2 21.1 
Public health insurance  66.1 61.8 42.1 
Body mass index, kg/m2 27.9 (5.6) 29.4 (5.8) 25.6 (4.2) 
Weight, kg 80.8 (20.0) 85.9 (20.0) 74.2 (14.4) 
Height, m 1.7 (0.1) 1.7 (0.1) 1.7 (0.1) 
Diabetesa 27.4 23.6 15.8 
Primary Cause of Liver Disease     
Hepatitis C/viral-other 43.6 49.1 52.6 
Alcoholic Hepatitis 29.0 25.5 5.3 
Other liver diseases 27.4 25.5 42.1 
Hepatocellular Carcinoma 13.4 40.0 79.0 
Weight loss per month on waitlist    
< 0‒≤ 5% 26.2 16.4 10.5 
> 5% 37.7 43.6 63.2 
MELD at registrationb 21.5 (16–31) 13 (9–17) 10 (7–14) 
MELD pre-transplantb 29.5 (22–37) 15 (11–24) 12 (9–13) 
Creatinine 1.5 (1.0–3.0) 0.9 (0.7–1.5) 0.9 (0.8–1.1) 
Total bilirubin 8.6 (3.8–18.8) 2.8 (1.4–6.4) 1.5 (0.9–3.4) 
International Normalized Ratio 2.0 (1.7–2.6) 1.3 (1.1–1.7) 1.2 (1.1–1.4) 
Albumin 3.1 (2.5–3.4) 2.9 (2.4–3.3) 2.8 (2.6–3.5) 
Child Pugh    
B 4.8 38.2 47.4 
C 95.2 52.7 26.3 
Portal Vein Thrombosis 17.7 14.6 10.5 
Medical condition    
Not Hospitalized 9.7 85.5 94.7 
Hospitalized, not ICU 46.8 10.9 5.3 
ICU 43.6 3.6 0 
Life support 22.6 3.6 0 
*%, mean (standard deviation), or median (interquartile range) 
aDiabetes type 1, 2, or unspecified 
bLaboratory-calculated MELD score 
 
IQR: interquartile range; kg: kilograms; m: meters; MELD: Model for End-Stage Liver 
Disease; n: number 
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Supplemental Table 3.5: Rate of muscle wasting versus functional status pre-transplant: 
stratified distributions and correlations, UMass liver transplant recipients 2006‒2015 (n = 
136) 
 
 Functional impairment/disability  
 
Sarcopenia,  
Rate of change* na 
Severe 
 (n = 62) 
Moderate 
 (n = 55) 
None 
 (n = 19) Correlationb 
(p-value)    
All 131 
-0.66 
(-2.62 to -0.12) 
-0.29 
(-1.43 to 0.56) 
-0.20 
(-0.53 to 0.02) 
0.31 (< 0.001) 
Age in years      
< 55 55 
-0.83 
(-3.71 to -0.12) 
-0.23 
(-1.43 to 1.82) 
-0.08 
(-0.31 to 0.25) 
0.36 (< 0.01) 
≥ 55 76 
-0.63 
(-2.62 to -0.00) 
-0.39 
(-1.39 to 0.26) 
-0.33 
(-0.65 to -0.09) 
0.25 (0.03) 
Gender      
Women 42 
-0.52 
(-2.62 to 2.91) 
-0.06 
(-0.95 to 0.56) 
0.45 
(-0.57 to 6.54) 
n/ac 
Men 89 
-0.72 
(-2.5 to -0.33) 
-0.50 
(-1.43 to 0.52) 
-0.21 
(-0.53 to -0.09) 
0.30 (< 0.01) 
Primary Liver Disease      
Hepatitis C/viral 63 
-0.72 
(-2.44 to -0.13) 
-0.25 
(-1.51 to 0.26) 
-0.20 
(-0.36 to -0.09) 
0.34 (< 0.01) 
Alcohol, Other 68 
-0.65 
(-5.55 to 1.50) 
-0.37 
(-1.30 to 0.66) 
-0.18 
(-0.63 to 0.13) 
n/ac 
Hepatocellular carcinoma      
None 82 
-0.90 
(-2.80 to -0.20) 
-0.25 
(-1.95 to 0.26) 
-0.20 
(-0.28 to 6.18) 
0.37 (< 0.01) 
Present 42 
-0.21 
(-0.56 to -0.05) 
-0.35 
(-1.02 to 0.67) 
-0.20 
(-0.63 to 0.02) 
n/ac 
Child-Pugh      
A or B 43 
-0.33 
(-0.65 to -0.18) 
-0.18 
(-1.21 to -0.75) 
-0.20 
(-0.53 to 0.02) 
n/ac 
C 88 
-0.72 
(-2.69 to -0.03) 
-0.39 
(-1.51 to 0.04) 
-0.20 
(-0.36 to -0.18) 
0.28 (< 0.01) 
*Sarcopenia: Relative change in Lean Psoas Area (LPA) per month = [(LPA within 90 
days before transplant–Baseline LPA)/ Baseline LPA/ months between CT scans], 
median (interquartile range) 
aSamples included in stratified analyses; correlations not reported for groups with not 
sufficiently powered (< 80%; see appendix 3C for details). 
bCorrelations were assessed using Spearman’s rho for rank-order correlation between 10-
point Karnofsky Performance Status scale and continuous sarcopenia and restricted to the 
range of lean psoas area values for which test assumptions were not violated: below (+) 
20% increase in the rate of relative Lean Psoas Area change/month (see appendix 3B for 
further detail on this determination). 
n: number; n/a: not applicable; p: probability 
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Appendix 3A. Assessing Intra-Rater Reliability of psoas muscle measurement 
Intra-observer reliability for measures of muscle mass (cross-sectional area, density) were 
assessed using Test-Retest methodology and confirmed before initiating primary study 
data collection. This approach involves re-ascertainment of the same subjects, using the 
same tools, and administered by the same research staff, ideally 2 weeks apart to prevent 
recall bias (221). We used images from patients who did not otherwise meet study 
inclusion criteria. Power calculations determined a sample that was 5% of the target 
study sample (n = 125), which included 4 images per patient, would be sufficient to 
determine good reliability, defined as ≥ 90% correlation using Pearson’s Correlation 
Coefficient. Correlation between the identical images measured 2 weeks apart was found 
to be 97%.  
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Appendix 3B. Assessing correlation assumptions 
We assessed linear and monotonic assumptions of correlation (for Pearson’s and 
Spearman correlation, respectively) by exploring scatter plots and LOWESS-weighted 
curves for 10-point Karnofsky Performance Status scale versus rate of muscle wasting (% 
change in lean psoas area (LPA)/month). Based on the LOWESS results in the first graph 
below, which shows that the association reverses direction past a certain (extreme) point 
and potentially parabolic 
relationship between the 2 
variables, we explored a 
squared transformation of 
LPA rate. A linear 
regression model was run 
with functional status as the 
dependent variable and 
LPA rate plus a squared 
(positive value) 
transformation of the LPA 
rate to test whether this was 
the case (yes if p-value of 
squared variable was 
significant), and in order to 
quantify point of inflection 
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where the effect reverses (-B1(LPA rate)/[-2*B2(LPA rate2)]). Transformation of the 
primary independent variable was decided against in order to simply the primary variable 
of interest and allow for ease of interpretation from a clinician perspective. Instead, 
correlations were assessed in the subset of the sample for which the monotonic form in 
the relationship between variables held (uniform direction of effect – no reversal). After 
exploring potential explanations for the 5 unlikely values of increasing LPA at a rate of > 
20%/month, we were unable to determine a definite explanation that would have 
otherwise been considered a conceptually important exclusion criteria.  
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Appendix 3C. Power calculations for minimum correlation detectable 
Assuming normal distributions of both sarcopenia and functional status variables, a 
sample size of 131 subjects (after applying exclusions described in Appendix B), an alpha 
of 0.05 and power (1-beta) of 0.80, with a null correlation of 0: the smallest correlation 
detectible is 0.24 for a two-tailed test (weak correlation). A correlation weaker than 0.24 
may not be detected in our analyses given these parameter restrictions. 
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Appendix 3D. Tests of significance for descriptive statistics 
Appropriate tests were selected based on normality of the dependent variable, as follows:  
• For normally distributed continuous variables: t-tests, paired t-tests for baseline 
versus pre-transplant comparisons, ANOVA 
• For skewed continuous variables: Wilcoxon rank-sum for unmatched pairs or 
signed-rank for pairs (baseline versus pre-transplant psoas measures) 
• For categorical variables: chi-squared (χ2) or Fischer’s exact for cell sizes < 5 
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